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Toward the Clinic: Understanding 
Patient Perspectives on AI and 
Data-Sharing for AI-Driven 
Oncology Drug Development
Roberta Dousa
Abstract
The increasing application of AI-led systems for oncology drug development 
and patient care holds the potential to usher pronounced impacts for patients’ 
well-being. Beyond technical innovations and infrastructural adjustments, research 
suggests that realizing this potential also hinges upon patients’ trust and under-
standing. With the promise of precision oncology predicated on a data-driven 
approach, public and private survey studies indicate patients view the lack of 
clarity surrounding data privacy, security, and ownership as a growing concern. 
Assuming an in-depth, semi-structured interview protocol, this qualitative study 
examines cancer patients’ perceptions of the burgeoning development of AI-led 
systems for oncology as well as their perspectives on sharing health data (including 
genetic data) for drug development. This article seeks to provide greater insight 
into the legal and ethical challenges that surround the application of these tools and 
to explore patient-centered approaches to building the frameworks of trust and 
accountability crucial to transferring these advances to the clinic.
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1. Introduction
Recent decades have witnessed major advances for AI systems, which has 
subsequently resulted in increased interest in applying AI-driven technologies for 
oncology drug development and cancer patient care. Beyond technical and infra-
structural adjustments, improvements, and innovations, recent studies suggest 
that realizing the potential of AI in healthcare and applying data-driven models 
to oncology drug development hinges in part upon the public’s—with especial 
regard to potential patients’ and users’—trust and understanding. As contingent to 
oncology drug development and research, the importance of the public’s capacity 
for trust extends to both the use of AI and data-sharing. Public and private survey 
studies indicate patients view the lack of clarity surrounding data privacy, security, 
and ownership as a growing concern. Exemplifying this, in September 2018, a 
KPMG survey of over 2000 Britons found that 51% of its participants were both 
worried about data privacy and unwilling to share personal data with U.K. organi-
zations for AI research and use [1]. In addition, the U.K.’s Academic Health Sciences 
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Network, in conjunction with the Department of Health and Social Care, released a 
report delineating the results from a 2018 “state of the nation survey.” Similar to the 
findings of the KPMG survey, this report, titled “Accelerating Artificial Intelligence 
in Health and Care,” identified that, according to pioneers in the field, the “overall 
enablers” to realizing the potential of AI in health and care include an ‘ethical 
framework to build/preserve trust and transparency’ as well as “clarity around 
ownership of data” [2]. Likewise, when asked, “which of the following areas do 
you think will be the greatest problem for artificial intelligence,” the KPMG survey 
respondents’ top answer was “data privacy and security.”
As patients increasingly view the lack of clarity surrounding data privacy, secu-
rity, and ownership as a growing concern, the potential benefits of AI-led oncology 
drug development and oncology care systems must not be accepted as superseding 
their potential to enact social harm. As public and patient approval and participa-
tion contribute to the use and development of these systems is imperative to study 
patient perceptions of AI and AI-led oncology drug development endeavors and to 
heed and address public concerns. Accordingly, this chapter enlists and examines 
ethnographic, textual, and other qualitative data that the author has assembled 
in pursuing a broad examination of the legal, political, and ethical imperatives 
surrounding the development of AI-driven systems for healthcare and for oncol-
ogy, specifically. This chapter provides new evidence for understanding patient 
reception of the development and deployment of these systems as well as patients’ 
perceptions and willingness to participate in health-related AI development by 
sharing medical data, necessary to build these systems and advance their efficacy, 
with the public and private entities engaged in developing them. Rooted firmly in 
interview work produced utilizing an in-depth, semi-structured interview protocol 
this chapter offers insights into the legal and ethical quandaries that surround the 
application of these tools in order to ultimately explore and assess patient-centered 
approaches to building crucial frameworks of trust and accountability fundamental 
to transferring these advances into clinical settings for the betterment of patient 
outcomes.
This chapter opens by offering a contextual scaffolding to understanding the 
terms AI and machine learning. Subsequently, the author provides an introductory 
overview to understand how AI-led systems might be applied to clinical contexts 
and oncology setting, respectively. This is followed by a discussion of some practical 
considerations and challenges to AI-enabled healthcare applications. The author 
then provides an overview of the study’s methods and methodology to further con-
textualize the remaining discussion, which relies heavily upon the author’s original 
qualitative research. This leads to a discussion of patient perceptions, knowledge, 
and concerns regarding AI-driven systems for oncology, drug development, and 
medicine, more broadly. Immediately after, the author stages an exploration of 
patient perceptions and concerns regarding sharing their medical data to bolster AI 
and oncology drug development research. The final section of this chapter discusses 
further patient-centered recommendations and proposals for ensuring patient 
trust, participation, and safety pertinent to increasing the development and clinical 
use of AI systems for oncology.
2. Defining AI and machine learning
2.1 Defining AI systems and intelligence
Although conceptions of sentient, machinic animacies can be traced as far back 
as antiquity, the understanding of “AI” or “artificial intelligence” as a term and field 
3Toward the Clinic: Understanding Patient Perspectives on AI and Data-Sharing for AI-Driven…
DOI: http://dx.doi.org/10.5772/intechopen.92787
of study originated in 1956 following a conference organized at Dartmouth College 
by the American computer scientist, John McCarthy. McCarthy, who himself coined 
the term, is often hailed as a preeminent pioneer of AI McCarthy defined artificial 
intelligence as “the science and engineering of intelligent machines” [3]. The ensu-
ing decades saw the salad days of what the analytic philosopher John Haugeland 
names as “Good Old Fashioned AI” (GOFAI). Within the paradigm GOFAI, artifi-
cial intelligence essentially referred to “procedural, logic-based reasoning and the 
capacity to manipulate abstract symbolic representations” [4]. For instance, the 
commercial “expert systems” of the 1970s and 1980s are typically understood as 
exemplifying GOFAI. By 1969, however, data scientists began to seriously question 
the general viability of AI as well as the initial, florid promise that surrounded 
these systems. The deflation of these experts, coupled with considerable decreases 
in grant support and research output, led to an “AI winter,” which lasted approxi-
mately for the next 20 years until a renewed interest in machine learning techniques 
propelled AI research forward [5].
In contrast to GOFAI, the “intelligence” at stake in contemporary AI systems 
is typically understood to imbricate machine learning techniques. Intelligence, in 
the current paradigm, is thought to derive from systems’ abilities to detect patterns 
across vast datasets and predict outcomes based on probability statistics. In other 
words, today algorithmic systems are deemed AI provided they process and analyze 
vast amounts of data, beyond the scope of an individual human, in order to predict 
and automate certain activities. Critical to understanding AI’s consequences for 
epistemology and social practice, anthropologist of technology M.C. Elish stresses 
that “the datasets and models used in these systems are not objective representa-
tions of reality” as systems that utilize machine learning techniques “can only be 
thought to ‘know’ something in the sense that it can correlate certain relevant 
variables accurately” [4].
With some cognizance of the shifting valences the term accrued in decades 
since the 1950s, AI might be otherwise understood as “a characteristic or set of 
capabilities exhibited by a computer that resembles intelligent behavior” although, 
evidently, delimiting what might be understood as “intelligence” remains a crucial 
although unresolved and contested dimension in defining AI [6]. Some researchers 
consider artificial intelligence to be contingent on behavioral demarcations, osten-
sible when a “computer can sense and act appropriately in a dynamic environment” 
[6]. Others link intelligence to symbolic processing, exhibited, for instance, when a 
system can recognize and respond appropriately to speech [6].
2.2 Machine learning: “imposing a shape on data”
Given the breadth of the term’s inherent contestations, evolutions, and stub-
born fluidity, social researchers of technology such as Tim Hwang and M.C. Elish 
contend that definitions of artificial intelligence and intelligent systems might be 
appropriately understood as “moving targets.” Rather than possessing a static set 
of demarcations signaling intelligence, artificially intelligent systems are defined 
in relation to “existing beliefs, attitudes, and technology” [6]. They argue that the 
rhetorical power of “artificial intelligence” is found in its “slipperiness”: seemingly 
everyone has an idea of what AI is, and yet everyone’s notion is different [6]. In 
consequence, data scientists and engineers today tend to shy away from the term 
“artificial intelligence.” Indeed, the equivocality of “artificial intelligence” has siloed 
“AI” as a marketing term rather than a technical one [4].
Current research in artificial intelligence occurs primarily in the field of 
machine learning (ML). Although “machine learning” was coined in 1959, signifi-
cant interest in these techniques did not follow until the 1980s following further 
Artificial Intelligence in Oncology Drug Discovery and Development
4
developments in techniques such as neural networks. Digital medicine researcher, 
Eric Topol argues that machine learning can be understood as “computers’ abil-
ity to learn without being explicitly programmed, with more than 50 different 
approaches like Random Forest, Bayesian networks, Support Vector machine uses”; 
they are “computer algorithms [that] learn from examples and experiences (data-
sets) rather than predefined, hard rules-based methods” [5]. Computer scientist 
Tom Mitchell has elaborated what that “learning” in the context of ML systems 
refers to. Mitchell writes: “A computer program is said to learn from experience E 
with respect to some class of tasks T and performance measure P if its performance 
at tasks in T, as measured by P, improves with experience E” [7].
Put differently, media and communications scholar Taina Bucher explains that 
although “algorithms are ‘trained’ on a corpus of data from which they may ‘learn’ 
to make certain kinds of decisions without human oversight…machines do not learn 
in the same sense that humans do.” Rather, Bucher argues, “the kind of learning 
machines do should be understood in a more functional sense” [8]. Citing legal 
scholar Harry Surden, Bucher explains that machine learning-driven systems are 
“capable of changing their behavior to enhance their performance on some task 
through experience” [8].
Machine learning is largely enabled by “proliferating data from which models 
may learn.” It follows that enormous datasets are paramount for developing effec-
tive ML systems. Machine learning techniques such as logistic regression models, 
k-nearest neighbors, and neural networks generally “pivot around ways of trans-
forming, constructing, or imposing some kind of shape on the data and using that 
shape to discover, decide, classify, rank, cluster, recommend, label, or predict what 
is happening or what will happen” [9]. Bucher underscores that what determines 
whether to use one technique over another “depends upon the domain (i.e., loan 
default prediction vs. image recognition), its demonstrated accuracy in classifica-
tion, and available computational resources, among other concerns” [8].
Machine learning systems are distinct from deterministic algorithms in that 
“given a particular input, a deterministic algorithm will always produce the same 
output by passing through the same sequence of steps” while an ML algorithmic 
system “will learn to predict outputs based on previous examples of relationships 
between input data and outputs” [8]. In other words, Bucher notes that “in contrast 
to the strict logical rules of traditional programming, machine learning is about 
writing programs that learn to solve problems by examples...using data to make 
models that have certain features” [8]. Feature engineering involves “extracting 
and selecting the most important aspects of machine learning” [8]. Signaling the 
constructed subjectivity of the knowledge produced by systems utilizing machine 
learning techniques, Bucher explains that “the understanding of data and what 
it represents, then, is not merely the matter of a machine that learns but also of 
humans who specify the states and outcomes in which they are interested in the first 
place” [8].
3. AI systems for oncology and oncology drug development
3.1 AI-enabled medical care
AI systems have been deployed in healthcare contexts since at least the 1970s 
following the development of computer-assisted clinical decision support tools, 
however the last decade is particularly thought to have been a watershed moment 
for the nexus of AI systems and healthcare. The advent of so-called big data analyt-
ics coupled with crucial advances in machine learning techniques (specifically, the 
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exponential development of new deep learning algorithms), has propelled both the 
development of, and a far-reaching rejuvenated interest in, applying these models 
for medical usage. This has compelled technologists, medical researchers, venture 
capitalists, and media pundits, among others, to question whether the contempo-
rary is witnessing the dawning of a new era of medicine. In the past several years 
alone, leading-edge advances in machine learning have enabled AI-driven systems 
to accurately identify heart rhythm abnormalities, predict suicides at a better 
rate than mental health professionals; to successfully interpret pathology slides 
of potential neoplastic tissues or medical scans with the same rate of accuracy 
(at times, even exceeding the rate of accuracy) of that of senior pathologists and 
radiologists; and to accurately diagnosis both a multitude of eye ailments such as 
diabetic retinopathy as well as some skin cancers at a similar rate to (and in some 
instances, better than) medical professionals [5]. Beyond these examples, other 
current efforts are directed at training AI systems to identify modifications in drug 
treatment protocols and to predict clinical outcomes.
3.2 AI-enabled cancer care
These celebrated developments, as well as a host of others, have led research-
ers in oncology-related fields to question how AI systems might be deployed 
to improve clinical outcomes for patients with cancer. Health researchers are 
emboldened by the promise that any piece of medical data able to be translated 
analytically such as “patterns, predictable outcomes, or pair associations” can 
be effectively evaluated by machines [10]. Currently, AI-based approaches to 
clinical trial design, pathology, and radiology are being studied for effectiveness 
with encouraging results. Under development are other promising applications of 
AI For example, data and medical scientists are endeavoring to integrate and ana-
lyze individuals’ multi-omics data (such as individuals’ genomes) using AI The 
ultimate goal of this cooperative research is to usher in a new standard of tailored 
or personalized medical care with the potential to improve clinical outcomes for 
patients with cancer. While some researchers and data scientists are pursuing the 
deployment of multi-omics data to improve early diagnosis in oncology, others 
are hoping AI-enabled approaches will aid in the continuing discovery of new and 
increasingly sensitive biomarkers for cancer care [10]. Healthcare professionals, 
researchers, and data scientists hope that, in the near future, complex biomarkers 
will constitute an improved basis for cancer prevention and diagnosis, offering 
patients the most optimal treatments based on the particular characteristics 
of their cancer, and aid medical professionals in determining the likelihood of 
 recurrence [11].
4. Practical considerations and challenges to AI-enabled healthcare
4.1 Contextualizing the hype: AI limitations
Accompanying the renewed interest in applying machine learning techniques 
to health data has been a buzz of exaggerated claims and overdrawn expectations 
regarding how quickly and comprehensively AI will transform modern medicine. 
Digital medicine researcher Eric Topol offers a partial list of the “outlandish expec-
tations” escorting the development AI-enabled healthcare. Some envision that soon 
these systems will “outperform doctors at all tasks; diagnose the undiagnosable; 
treat the untreatable; see the unseeable on scans and slides; predict the unpre-
dictable; classify the unclassifiable; eliminate workflow inefficiencies; eliminate 
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hospital admissions and readmissions; eliminate the surfeit of unnecessary jobs; 
result in 100% medical adherence; produce zero patient harm; and cure cancer” [5]. 
Instead, Topol and other medical researchers assume a more modest view: AI-driven 
systems will not serve as a panacea to all the aforementioned predicaments in 
modern healthcare but will instead gradually serve as an increasingly important tool 
in addressing these and other issues. Moreover, medical experts and technologists 
alike contend that the encouraging results AI-driven systems have garnered in fields 
like pathology and radiology, for example, should be taken neither as a justification 
for the outsourcing of pathologists and radiologists, nor point to the burgeoning 
obsolescence of medical specialists as a whole [10]. Rather, they stress that these 
initial successes should be understood as an “indication that their workload could 
be optimized and, importantly, the waiting time for patients to receive a diagnosis 
can be reduced” [10]. In this perspective, over time, the widespread adoption of 
AI systems in healthcare will result in a crucial leveling of the “medical knowledge 
landscape” [5]. As a consequence, some medical researchers believe that advances 
in AI and the eventual adoption of these systems within the realm of healthcare will 
herald unprecedented advantages to modern medical specialists by “restoring the 
gift of time” to health professionals allowing them to devote more clinical attention, 
emotional support, and guidance to patients [5].
4.2 Tempering visions of imminent medical revolutions
While in the past decade, the development of AI systems for use in the medical 
field has certainly progressed and led to feats that have garnered significant atten-
tion, these successes remain arguably limited and the progression of these systems 
decidedly gradual. Taking the field of narrow AI diagnostics as an example, recent 
systems have accurately diagnosed skin lesions and pathology slides in the realm of 
oncology. In cardiology, AI diagnostic systems have accurately interpreted echocar-
diographic images and electrocardiograms in diagnosing heart abnormalities [5]. 
Other AI diagnostic systems have successfully analyzed audio-wave forms to assist 
in diagnosing asthma, pneumonia, tuberculosis, and other lung ailments [5]. All of 
these successes, however, constitute narrow AI tools that, in reasonable estimations, 
would serve to aid rather than replace medical professionals. Demonstrably, one 
broad AI diagnostic system sits in recent memory of some oncologists as a stunning 
failure that highlights the limitations of AI-enabled healthcare at present. From its 
early inception, IBM’s AI-driven Watson supercomputer was hailed by the company 
as harnessing the power to revolutionize cancer care. Beginning in 2013, IBM initi-
ated partnerships with leading medical institutions renowned for their research in 
oncology such as the MD Anderson Cancer Center at the University of Texas, the 
Memorial Sloan-Kettering Cancer Center in New York, and the University of North 
Carolina’s Lineberger Comprehensive Cancer Center. IBM bought a multitude of 
competitor companies and spent millions in order to train Watson on crucial medi-
cal data including biomedical literature, patient histories and data, billing records, 
and medical histories. Although Watson had some success at the University North 
Carolina in identifying relevant clinical trials for patients and suggesting potential 
treatments based on its ability to ingest peer-reviewed biomedical literature, Watson 
was deemed a stunning failure and scrapped by MD Anderson in early 2016 follow-
ing missed deadlines, a series of fruitless pilot projects, and continuous changes to 
the types of cancer that would harness Watson’s focus. Watson’s problems at MD 
Anderson involved a limited ability to understand and suggest actionable insights 
from the medical data it ingested was made worse by fragmentary clinical data and a 
lack of evidentiary support in the studies it analyzed. Costing MD Anderson over 62 
million dollars before its collapse, investing in Watson proved a remarkable blunder 
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for the cancer research center [12]. A former manager at IBM asserts a further 
reason as to why the project failed miserably in its lofty efforts to transform oncol-
ogy. In his estimation, IBM “turned the marketing engine loose without controlling 
how to build and construct a product” [5]. Topol summarizes that while “there 
is certainly potential for computing to make a major difference [in medicine and 
oncology more broadly]... so far there has been minimal delivery on the promise.” 
Topol contends that the difficulty in assembly and aggregation of data has been 
underestimated, not just by Watson, but a myriad of tech companies venturing into 
healthcare [5]. The hype surrounding AI-enabled healthcare tools and indeed, the 
fortunes at stake, leads technology producers, marketers, commentators, investors, 
patients, and medical specialists to overestimate the speed of development and 
delivery of AI systems and, can result in ungrounded and uncritical conceptions of 
their potential to make significant, comprehensive impacts on medical care and of 
the liabilities these technologies can incur.
4.3  Defining standards and ensuring quality access to care in a context marked 
by enduring health inequities
Beyond a modest view for the rates of widespread AI development and deploy-
ment, potential of instantiations of AI-enabled healthcare also brings other critical 
considerations and challenges to the fore. One of the current challenges hamper-
ing AI-enabled approaches for routine use in clinical settings involves the lack of 
appropriate coherency regarding what constitutes standardization regarding these 
tools. The disparate development of tools utilizing machine learning techniques has 
produced a paradigm in which the same clinical question is addressed by separate 
systems developed in independent institutions. Validated on particular and dis-
tinct datasets or samples, these systems may produce different outputs, which can 
ultimately result in differing clinical recommendations and patient outcomes [10]. 
For example, pathologists can disagree whether a biopsy sample taken from a breast 
tissue is cancerous, which some studies suggest has contributed to an over-diagnosis 
of breast cancer. The subtle abnormalities exhibited by small, early-stage cancers 
are particularly difficult to diagnose. This issue extends beyond breast cancer 
to diagnosing melanomas, thyroid cancer, and prostate cancer. Existing clinical 
disagreement over what constitutes cancer may lead to cancer screening AI tools 
that mimic a tendency for over-diagnosis [13].
When applying an AI-driven tool in a clinical scenario, clinicians and other 
health professionals across institutions and national borders must have definitive 
assurances of scalable clinical standardization to deliver appropriate quality of 
care. Consequently, this requires international collaboration that must necessarily 
involve technology producers, clinical specialists, and regulatory bodies. Moreover, 
ensuring all patients have access to state of the art, AI-driven healthcare remains 
a significant challenge. Similar to other new technologies, experts predict that 
AI-enabled medical tools will be extremely costly for health institutions initially 
and will gradually decrease in expense over time. Given the potential of, for exam-
ple, more timely diagnosis and improved disease monitoring made possible by AI 
tools, patients being treated at medical centers able to afford AI resources are likely 
to experience better health outcomes than those at institutions without the financial 
means to invest in these expensive resources. In addition to possessing considerable 
economic resources, medical centers may also need to train health professionals in 
the workings and use of these tools, which presents another potential hurdle to the 
widespread deployment of these systems.
Furthermore, the U.S.-based research of both professor of medicine and clinical 
surgery at the University of Illinois, Robert A. Winn, and anthropologist Kadija 
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Ferryman of the Data and Society Research Institute, enjoins them to contextualize 
AI-driven success stories in medicine—especially in the realm of cancer care—
against the backdrop of enduring health disparities in the United States. Although 
health expenditures in the U.S. are colossal with healthcare constituting more than 
18% of the United States’ gross domestic product (climbing more than 10 percent-
age points since 1975), increased healthcare spending has not corresponded to 
improved healthcare outcomes across population groups in the U.S. [5]. Ferryman 
and Winn stress the sobering fact that people of color continue to have dispropor-
tionately higher incidence and mortality rates for multiple cancers (among them: 
kidney, breast, cervical, and prostate cancer) as they pose the following question: 
“As big data comes to cancer care, how can we ensure that it is addressing issues 
of equity, and that these new technologies will not further entrench disparities in 
cancer?” [14]. Winn and Ferryman join other medical researchers in arguing that 
not only does a shift in increased usage of medical AI tools necessitate population-
representative data accessibility coupled with regulatory paradigms to ensure 
standardization and quality, but it also requires prioritizing healthcare equity, 
ethical health mandates, and inclusivity [15].
For example, Winn and Ferryman bring attention to how such a shift would 
impact the clinical responsibilities of health professionals. They reason that due 
to the nature of clinical care, clinicians must be able to assess, understand, and 
explain machine learning-driven systems to patients. Consequently this necessitates 
a certain level of transparency in how these systems are trained, developed, and 
produce outputs; these systems cannot be fully “black-boxed.” With the capacity of 
these technologies to refigure clinicians’ responsibilities, Winn and Ferryman echo 
a chorus of legal scholars who forewarn that a more robust integration of AI tools in 
clinical settings may incur both a transformation of the patient-doctor relationship 
as well as a reconceptualization of the regulations surrounding malpractice. Winn 
and Ferryman further contend that a shift in clinicians’ liabilities and obligations to 
demystify AI systems for patients may incur higher stakes for patients with “lim-
ited access to high quality clinical care, limited health literacy, earned mistrust of 
medical providers, and those individuals who may be exposed to interpersonal and 
institutional racism and discrimination in their healthcare encounters” [14]. They 
argue that it is critical that the potential ramifications for vulnerable patients due 
to the integration of AI technology in the clinic be not only acknowledged but also, 
consistently and intentionally managed. Together, these aforementioned challenges 
consist of only a small sampling of the issues that must be addressed before a suc-
cessful, widespread adoption of AI-driven medical tools can be undertaken.
5. Methods and methodology
This chapter is informed by and enlists textual, ethnographic, and other qualita-
tive data that the author has collected in undertaking a broad examination of the 
legal, political, and ethical imperatives surrounding the development of AI-driven 
systems for healthcare and for oncology, specifically. This study attends to patient 
reception of the development and deployment of these systems as well as patients’ 
perceptions and willingness to participate in health-related AI development by 
sharing medical data necessary to train and improve these systems with public and 
private entities engaged in developing them.
This analysis draws upon qualitative research methods including textual and 
content analysis of academic literature reviews, general audience media, and 
industry-oriented publications. This study was further augmented by an in-depth, 
semi-structured interview protocol. In addition to attending cancer patient 
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conferences, talks, and support groups, the author conducted interviews with 40 
relevant stakeholders. The approximately 15 hours of observation and 40 interviews 
were undertaken for the first 11 months of 2019. Interlocutors included cancer 
patients and their caregivers, cancer patient advocates, directors and specialists 
at cancer care nonprofits, technologists employed at firms developing AI tools for 
oncology, and clinicians. The interview corpus of this study includes 9 U.S. citizens, 
29 U.K. citizens, and 5 citizens from the European Union. Interviews were primarily 
conducted in cities located in Northern California in the U.S. as well as in London 
and Cambridgeshire in the U.K.
Among the interview corpus, 28 individuals are cancer patients who were 
actively undergoing treatment or who were in remission at the time of the inter-
view. Seven patients were in remission at the time the interviews were conducted 
and the remaining 21 patients are currently receiving treatment for their cancers. 
Twenty-four of the patients were born between 1939 and 1960.The four remaining 
patients were born after 1983, the youngest patient interviewed was born in 1990. 
The majority of the patients interviewed are retired from the workforce having had 
previous careers as secretaries, telecom and systems engineers, insurance salesmen, 
military logisticians, child-care providers, librarians, photographers, teachers, 
and small-business owners. At the time of the interviews, patients in the interview 
corpus who were in the workforce had employment as data scientists, teachers, 
lab technicians, and engineers. Those with employment were generally employed 
as part-time employees as a result of their continuing treatments. Other patients 
were stay-at-home parents and one patient is a doctoral student. When asked about 
socioeconomic status, most patients considered themselves to be middle-class. 
The patients in this interview corpus are of white, European descent although the 
interview corpus as a whole and the ethnographic work that supplements this study 
involved patients, advocates, and healthcare professionals from other ethnic and 
racial backgrounds. The patients interviewed possessed a multitude of different 
cancer diagnoses. Three of the patients interviewed had received a diagnosis of 
colorectal cancer; six had received a diagnosis of breast cancer; two had received a 
diagnosis of cervical cancer; six had received a diagnosis of bladder cancer; five had 
received a diagnosis of prostate cancer; seven had received lymphoma diagnoses; 
four had received a diagnosis of myeloma; and, one patient had received a diagnosis 
of skin cancer (several patients had developed multiple cancers).
Three individuals within this interview corpus are clinicians. Two of these 
clinicians are senior oncologists with extensive experience working at illustrious 
cancer research hospitals in the United Kingdom, Ireland, Italy, and the United 
States. The final clinician is completing their initial rotation-years as a pediatrician 
at a premiere research hospital on the west coast of the United States; this clinician 
previously earned a doctorate degree in medical anthropology. Their disserta-
tion research studied patient data-sharing and patient reception of self-tracking 
approaches to medical care. Seven interviews were conducted with data scientists, 
bioinformaticians, and start-up founders who work or previously worked at a U.K. 
and U.S.-based AI oncology-related start-up.
The remaining five interlocutors comprising this interview corpus are trained 
cancer patient advocates. One of these patient advocates is a U.K. citizen and the 
remaining four are U.S. citizens. All are based in California although three of them 
occasionally serve as advocates and patient ethicists for projects at renowned cancer 
research institutes in other U.S. states. One of these advocates is a licensed nurse 
practitioner with experience in global health consultancy; this advocate currently 
serves as the program director of a nonprofit cancer care center and clinic located in 
a Northern Californian metropolis. Another cancer patient advocate in this corpus 
has nearly three decades of experience and has earned several awards and accolades 
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for her advocacy work. Previously, this advocate was employed as a patient advocate 
and advisor at an eminent national cancer support organization and is presently 
employed as a senior patient navigator with a focus on multicultural patient sup-
port at a California nonprofit that primarily caters to local, low-income women of 
color who have received cancer diagnoses although the organization remains open 
patients of all backgrounds. In her role, this advocate guides patients through treat-
ment, clinical trial options and hospital visits; assists patients with insurance forms 
and other medical paperwork; and provides patients with counseling and much 
needed psycho-social support. This advocate regularly serves on cancer patient 
advocate conference committees, counsels researchers seeking to work with cancer 
patients, and acts as a grant reviewer for emerging research ventures. The three 
remaining advocates have diverse employment histories in the fields of marketing, 
graphic design, emergency medicine, and nonprofit leadership. For nearly 15 years, 
these trained cancer survivor advocates with expertise in research and patient com-
munication have worked with national and local advocacy organizations serving on 
survivorship and research committees for various academic, nonprofit, and govern-
mental organizations. They frequently serve as research partners and advocates on 
scientific review committees and act as grant reviewers for emerging university-led 
research projects in the state of California. They also serve on clinical trials advisory 
committees as advocate observers, patient advisors, and stakeholder reviewers 
in partnership with state and national research bodies as well as national cancer 
research organizations including the National Institutes of Health, the American 
Cancer Society, the Department of Defense, and the Susan G. Komen Foundation. 
These advocates routinely volunteer at local nonprofits as helpline attendees and 
peer mentors to cancer patients currently undergoing treatment.
Coagulating and analyzing this qualitative data, this chapter offers insight into 
the perceptions and concerns some cancer patients (i.e., particularly those identify-
ing as middle class and of European descent), patient advocates, and clinicians 
abiding in the Home Counties of the U.K. and Northern Californian metropolises 
possess regarding both the deployment of AI systems for oncology as well as sharing 
health data with public and private entities for the purpose of developing these 
systems. Complementing the textual and ethnographic data, the interview work 
conducted enumerates popular dispositions toward biomedical technological devel-
opment for oncology within the socially stratified societies of the U.S. and the U.K. 
as well as refracts the particular exigencies of pursuing cancer treatments within the 
two nations’ contrasting healthcare systems.
Researchers studying the social and technical valences of AI continue to insist 
upon the foundational legitimacy and, indeed, the value of studying popular 
conceptions of machine learning-driven systems. Public perceptions contribute to 
the fashioning of the material and discursive realities these systems act upon and 
within and furthermore constitute collective contestations of the political realities, 
ethical liabilities, and financial viabilities immanent to the social production of 
these technological systems. Correspondingly, Monteescu and Elish contend that 
“When it comes to understanding the impact of AI, the social perceptions of a tech-
nology’s capabilities are equally important to technical definitions. Elsewhere we 
have observed that non-expert understandings of AI are often shaped by marketing 
rhetoric, which sometimes suggests capabilities that are not yet technically possible. 
For many developers of AI systems, this potential fuzziness is ‘not a bug but a fea-
ture,’ so to speak. The public perception of AI is often leveraged to drum up excite-
ment or stand in for a range of automated technologies that haven’t yet become fully 
actualized. The fluctuating understandings of AI will not be universally resolved, 
and so it is necessary to account for the consequences of AI as defined through both 
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technical definitions and social representations” [16]. Public trust, knowledge, 
and perception of health data-sharing and AI development and deployment will 
undoubtedly influence how governments, health organizations, and corporate 
entities continue to debate, contest, insist on, and invest in AI viability for medical 
usage. For this reason, public perceptions may also impact the material develop-
ment of these systems (e.g., via a collective willingness or unwillingness to use these 
systems for medical treatment or engage in health data-sharing for AI develop-
ment); the regulatory mandates and other frameworks of standardization, equity, 
and accountability pursued in their wake; the funding and long-term economic 
feasibility of these systems; and perhaps even the meaning of what medical care can 
or should constitute.
6.  Understanding patient perceptions of AI-driven systems for 
healthcare
This chapter presents an analytic overview of: the extent of knowledge a 
sample of U.S. and U.K. patients possess regarding AI systems for oncology and 
oncology-related drug development as well as healthcare, more broadly. Similar 
to other recent studies, the qualitative research that this discussion derives from 
indicates that general public audiences (inclusive of cancer patients) continue to 
possess varied notions of not only what constitutes AI, but also what capabilities 
these AI systems hold and the extent of proficiency with which they presently 
perform them. With varied (although certainly increasing) levels of sophistica-
tion, cancer patients (as evidenced in the interview sample) are questioning what 
potential ramifications patients should be aware of, and potentially concerned 
about, regarding the usage of AI systems for healthcare and oncology. They 
question what emotive and affective positions they should take with regard to 
AI Certainly, patients possess divergent understandings of both when and how 
this technology may impact or augment the standard of care within oncology 
that directs recommended treatment paths and contributes to patient outcomes. 
Nevertheless, many are attentive to the limitations of their current knowledge 
regarding these systems. In consequence, patients are questioning how they can 
stay informed, what constitutes trustworthy sources from which they can glean 
accurate and legible information, and what specific types of inquiries should they 
be attending to.
In order for healthcare technologies to be effectively responsive to patients’ 
needs, it is evident that institutions, persons, and entities involved in developing 
instruments that can affect cancer patients’ quality of care not only assess patients’ 
present knowledge and perceptions of emerging technology, but also heed and 
address their resultant questions and concerns. With a preponderant focus on ana-
lyzing the interview data the author has collected, this chapter assesses the express 
knowledge, perceptions, and suggestions a sample of U.S. and U.K. patients possess 
regarding AI systems for oncology and oncology drug development. Specifically, 
this chapter enumerates three primary analytical axes in attending to this dataset: 
cancer patients’ perception of AI systems for oncology; their willingness to contrib-
ute to the development of the efficacy of these systems and AI-drug development 
via medical data-sharing; the concerns they bear regarding both the deployment 
and integration of these systems as well as health data-sharing for the aforemen-
tioned purposes; and finally, the recommendations patients and relevant experts 
are proposing for building accountability measures to ensure both safe usage and 
improve patient trust.
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6.1 Patients’ expressed levels of knowledge
In characterizing the knowledge the patient interlocutors comprising the inter-
view corpus possessed at the time the interviews were conducted, it is principally 
important to register that the vast majority of these cancer patients had no formal 
or professional training in regards to these systems. While four of the patients 
offered examples demonstrating how they currently utilize or previously utilized 
machine learning systems in their employment, the remaining number (86% of 
the patient interlocutors) had no professional experience with these systems and 
learned about AI primarily through general audience media. All things considered, 
the interview data are largely representative then of not just modes of public 
perception but lay opinion. All of the patients, with the exception of one, registered 
having heard the term of AI and exhibited a capacity to grasp the foundations of its 
most basic principles. These interlocutors, moreover, often went on to demonstrate 
the applicability of AI tools or machine learning-driven systems within healthcare 
contexts. Furthermore, when offering examples, patient interlocutors chiefly cited 
examples from both oncology and general practitioner diagnostics. Those who 
demonstrated a familiarity of the application of machine learning systems to oncol-
ogy most frequently cited its current applicability to pathology, medical robotics, 
and multi-omics data-handling. Five patient interlocutors within the interview 
corpus related having previously prepared reports or presentations in which they 
offered an introductory overview of AI and AI applicability to oncology for either 
cancer patients and advocates, or otherwise general public audiences.
Unsurprisingly, the interviews exhibited a wide range of patient articulations 
of the foundational aspects of AI systems. For example, when asked what they 
knew about AI, one patient insisted that they knew “very little”; “I would assume 
it has something to do with algorithms. In [our support] group, we’ve talked about 
how there might be some algorithms that can be used for diagnostic tools for GP’s. 
To me, I don’t know if this is right, but AI has to do with data-handling. There’s so 
much data out in this world and we have to think about how are we going to make 
it useful.” After explaining that they first learned about the principles of AI from 
early science fiction novels (such as Isaac Asimov’s I, Robot), one patient defined 
AI in the following terms: “Well, I would say it is, basically, a computer that is 
capable of interpreting input, and making deductions from input that it is given. 
Obviously, the way it responds to that is being presumably programmed by a human 
being. But, I believe that computers, or at least AI, are capable of taking it beyond 
that, they’re capable of learning from the basic information they’re been given and 
building on that.” Another patient interlocutor explained: “Well, to my mind, AI 
is programming a computer of some sort to take various in-puts and to learn from 
them, basically. So if you got say, a visual system—cancers on an x-ray for example, 
you would have a system that you could teach. Say, put through a number positives 
or a number negatives of say a thousand scans and maybe a hundred of those are 
positive and you teach it to compare it to the negative ones and identify which ones 
are positive. Then you can leave it on its own to work by itself from that point on. 
Y’know once you are satisfied that it’s strike-rate is sufficient. You can leave it to 
its own devices. That’s how I kind of look at medical AI anyway. I also think AI is 
very much a black box, just from what I’ve seen on the telly. You set it going but you 
don’t necessarily understand how it’s doing it. [laughing]... Whether that’s true or 
not, I don’t know. But that’s my perception of it from the popular media I guess...I 
have no idea just how much AI is actually out there and performing at the moment, 
if you see what I mean. How far it’s come; how much use there is for it at present; 
whether it still remains a largely experimental field.” These three explanations offer 
a triangulation of the amount of knowledge and levels of coherency the majority of 
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the cancer patients interviewed expressed to the author. Many could give a rela-
tively clear articulation of how the elementary facets of machine learning or of how 
AI algorithms function. Typically, this sample of patients demonstrated that these 
systems function to process vast amounts of data, that with appropriate engineer-
ing and sufficient data training sets these algorithms can be “trained” to identify 
relevant variables as outputs, and that AI can be applied to medical data and have 
potential use for oncology.
Excluding the four patient interlocutors who have professional training in and 
experience with AI systems, patients related that they had arrived at their cur-
rent level of knowledge through general audience media. In particular, all of the 
remaining patient interlocutors cited two primary sources from which they derived 
knowledge regarding these systems. All related that they had learned about AI from 
journalistic sources and accounts they encountered via print media such as a local, 
national, international, or specialized newspapers (e.g., a business newspaper or 
magazine) and digital news platforms. Secondly, all related that they had gained 
an initial introduction to or a partial familiarity with the general principles of AI 
via speculative accounts found in genre fiction sources such as science fiction texts, 
films, and television series. Some indicated that accounts concerning AI in specula-
tive fiction or journalistic sources sparked a personal interest in these systems and 
their development; these patient interlocutors explained that they further bolstered 
their knowledge through nonfiction texts about AI development and applicability. 
Otherwise, patients related that they had further learned about AI via friends, 
spouses, or relatives who have professional involvement with AI Some reported 
having been informed by existing government reports (e.g., the U.K.’s 2018 House of 
Lords Report on Artificial Intelligence) that they were initially made aware of from 
journalistic sources. A small number of patient interlocutors indicated that they also 
learned about AI via their involvement in patient support groups or patient advo-
cacy work (including oncology-related conferences and involvement with medical 
research auditing).
6.2 Patients’ general perceptions of AI
Overwhelming, the cancer patients interviewed for this study held positive 
perceptions and opinions for the development of AI systems for oncology. With 
the exception of one patient interlocutor who admitted no knowledge and no 
opinions of these tools, the patient interlocutors comprising the interview corpus 
voiced hope for the relevancy and potential for AI development and application for 
medicine. Continuously, these patients insisted that as a “useful tool,” “able to catch 
things humans can’t,” AI systems would be a “step forward” inasmuch as they “will 
make things better” by “improv[ing] speed and quality of data analysis.” As one 
patient put it: “we’ve been waiting for a faster identification of things and this can 
only help.” Others noted with pronounced optimism that these tools may “reduce 
workloads” for medical professionals such as doctors and nurses. One patient 
mused that perhaps such systems could combat clinical biases and bigotry through 
objective and accurate data-handling; a view that has been critiqued by social 
researchers of technology as misguided. “Generally,” another patient concluded, “I 
think tech advances are a good thing.” Another interlocutor echoed this statement, 
adding: “It sounds great and I think it will give people confidence and perhaps a 
better chance at survival.”
Patients who possessed professional training or work experience in developing 
and deploying AI systems expressed similar hope and positivity about AI-enabled 
healthcare. One patient who works with AI tools as a lab technician within the 
context of drug development remarked that AI tools are “something in development 
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that can be really useful, especially for handling patient data and especially genom-
ics data... It’s really good for things that have a clear ‘yes’ or ‘no’ and beyond that 
there are always new improvements, new features to improve the algorithms with... 
If [AI tools for oncology] allow for the use of certain data like mutations and other 
genomics data, they could provide more confidence in the use of AI for cancer 
treatment predictions.” Two other patients, with tangential familiarity with AI 
systems given their respective professions as a statistician and systems engineer 
asserted that AI presented “a lot to be gained” and especially holds promise for the 
improvement of diagnostics. The systems engineer asserted his belief that, used 
in the arena of oncology, AI tools may “bring reliable indications for decisions that 
don’t get made or get lost in communication.”
Notably, many of the patient interlocutors interviewed characterized their 
perceptions of AI tools as thoroughly secondary and overshadowed by the cur-
rency and pervasiveness of popular teleological narratives of technology that cast 
technological development as both heroic and as “inevitable progress.” Concerning 
AI-enabled healthcare, patients frequently conceded: “It’s the way of the future.” 
In turn, some expressed that their conceptions of the inevitability of technological 
progression (in this instance, made manifest by AI tools for healthcare) encouraged 
feelings that “[The prospect of AI-enabled oncology] is exciting, but a little scary.” 
In other words, among declarations of the hope regarding the potential of AI, many 
patients voiced tepid fears in relation to offering their assessments of AI tools given 
their (and potentially others’) beliefs in the potential marginality of their own 
social locations—as, for instance, elders and, more broadly, as cancer patients. 
What would often begin as self-aware statements relating limited abilities to stay 
current with the seeming swiftness of many technological shifts and innovations, 
would in many interviews lead to remarks through which patients would minimize 
their relevancy and position to offer opinions, thoughts, or concerns about AI “Are 
we doomed?” one patient asked, “I don’t know. All I know is that [AI development] 
is unstoppable and frankly...you can’t put yesterday’s values on tomorrow.” Another 
insisted: “Everything is moving forward and does move forward. Why should this 
be any different? It’s how we live, and maybe we just need to get on and accept it.” 
Others voiced that regardless of the advancements in AI, they feel they are “too old” 
to “keep up” and described feeling as if they are suspended in a paradigm of being 
left behind with regard to their technological knowledge and savviness and have 
accepted this predicament as “their lot”: “Things move quickly and I’ve switched 
off.” In addition to age, patients pointed to their diagnosis and the rigorousness of 
their therapies as preventing them from seeing the future of AI development for 
oncology as pertinent to them. Patients interviewed in the middle of treatment 
cycles voiced a similar sentiment of being too sick to “keep up” or of not feeling 
capable of appropriately assessing how it would affect the future of oncology, let 
alone themselves and others. In fact, some patients asserted confidently: “[These 
tools] won’t affect me.”
Patients who were familiar with AI due to the nature of their professional 
employment admitted that while they firmly supported the technology’s use and 
development with great hope, in their view, these systems generally remain “under-
developed and under-utilized.” “Changes are happening,” these patients declared, 
“but slowly.” Likewise, one patient advocate related: “I’ve been hearing a lot about 
[AI tools for oncology] at conferences and it sounds wonderful but I haven’t seen it 
materialize yet in hospitals and clinics.”
In summary, some patients (often those with lay knowledge of AI systems) 
consider AI systems for oncology and medicine to be developing at a rapid rate 
and intertwine this conception of rapid technological development with a notion 
of “natural” and “inevitable” technological progression against which they would 
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unfavorably compare their age and health status as inversely related. In this view, 
their age and health status become barriers that immobilize their capacity to stay 
informed and interested in technological development. This logic perhaps serves as 
a basis for elaborating insecurities about whether they have an appropriate ability 
to speak lucidly or incisively about AI tools for oncology which, at times, results in a 
firm belief that they should not concern themselves with forming critical views and 
voicing judgments about the subject.
Beyond highlighting contrasting conceptions of the pace of AI development, 
patients framed their enthusiasm regarding AI systems for oncology with state-
ments conceding a general awareness that technological transition may produce 
vulnerabilities and risks for patients and medical staff. Despite widely expressed 
optimism, a majority of patients voiced that shifting to a greater use of AI tools for 
oncology and medicine may subject patients to additional risk for medical errors 
or mishaps. “There’s always room for errors and mistakes,” as one patient mused. 
“Errors,” another patient conceded, “are inevitable and it takes time to perfect 
technology. That’s progression. We learn by mistakes, sadly.” Further epitomizing 
this appraisal, a patient familiar with machine learning techniques explained: “If 
used for the benefit of mankind [sic], I am absolutely onboard for this tech. Bring 
it on. But forcing learning when the data isn’t there, isn’t the right thing to do.” In 
other words, despite an embrace of narratives of technological progression, patients 
voiced a desire for cautious progression of AI tools and emphasized the potential 
human costs of technological innovation and initial deployment.
Moreover, many patients indicated that they believe such tools may, in the 
future, produce some level of job insecurity for certain doctors and medical staff 
(e.g., radiologists, pathologists). Still, those who voiced this issue noted that they 
prioritized manifesting better health outcomes for patients over maintaining 
employment for medical professionals able to produce less satisfactory health 
outcomes. Others related that they believe that these tools will not encroach on 
the necessity of the roles of medical professionals or threaten their employment 
prospects but will instead produce “a major sea-change for the medical industry,” 
the consequence of which being that doctors and other medical staff will “need to 
be retrained or receive additional training.”
Finally, a small minority of patients experience the prospect of AI-enabled 
healthcare as shrouded in confusion and potential conspiracy. “I have concerns 
about it,” one patient admitted, “but only in a SciFi-horror film kind of way which 
is based on ignorance and a certain amount of misinformation.” Other patients 
related more earnest concerns about AI tools for healthcare regarding potential 
issues of developers’ nefarious intent, consolidated power, and misguided objec-
tives. One patient confessed these fears in the following manner: “In my way of 
understanding, ultimately, AI will be writing the software itself. And that’s where 
it goes out of control because from what I’ve seen, personally, and to the pres-
ent day, software engineers have a lot of power, a lot of power! And the people 
who write the software...they could conceal things, you get an unscrupulous one. 
Ninety-nine percent, I’m sure, are perfectly legitimate, but it only needs one or 
two unscrupulous ones who can put bugs in software. And it worries me that, as 
I say, ultimately, that software won’t be written by humans—the software itself 
will be interpreted and written by AI and I’m sure that’s ultimately where we’re 
going.” Other patients voiced wariness that there exists far too much control over 
the development and deployment of AI systems “in the hands of too few.” They 
stressed the need to democratize relations of power relating to how private enti-
ties and corporate structures consolidate the decision-making power over how 
and which issues are tackled with AI tools and consequently, how these tools are 
designed and implemented across sectors within and outside of medicine (e.g., the 
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workings of financial services companies and investment banks or the political 
encroachment and monopolistic tendencies of tech mammoths such as Amazon, 
Google, and Facebook). Some patients’ portends remained vaguely sketched: “Like 
all tech, evil men get behind it and we see the bad side of everything...Insert Blade 
Runner quote here.”
In parallel, other patients declared that although they felt generally optimistic 
about the prospects of AI developments for healthcare, they underscored a desire 
for these technologies “to improve quality of life, not extend it.” One patient 
admitted, “I don’t want AI to cure cancer in order for people to live forever.” 
Evidently, one patient advocate insisted, “The promise of Big Data is confusing 
for patients.” Patient interlocutors with technical expertise and familiarity with 
AI systems expressed their bafflement over other patients’ and public figures’ 
confusions regarding these systems. One of these patients voiced his frustrations 
regarding the philosophical or imaginative fears some lay members of the public 
have: “I don’t understand why people think it’s some Doctor Who-Take-Over-the 
World syndrome!...most people in the last 30-40 years, would have used computing 
techniques of some sort to break down their spreadsheet or whatever. Conceptually, 
I don’t see a great difference between AI and that….I can’t wrap my head around 
why people think it’s some sort of SciFi, Doctor Who thing or, why they think it’s 
something that’s been invented last week by Amazon. It’s been around thirty years 
or so and the math has been around for one hundred years! And secondly, they’ve 
been doing it all their lives!” While this patient thought it might aid others without 
expertise to understand what he understood as the banalities of AI by drawing 
conceptual comparisons to more simple computing properties, another suggested 
confusions and conspiracy theories could be attributed to idiomatic decisions. He 
explained: “I feel, sort of working in that area, that we should stop talking about 
artificial intelligence and talk more about machine learning or statistical learning. 
Talk about something different from artificial intelligence because when people 
think about that they think of Arnold Schwarzenegger and The Terminator. In fact, 
statistical techniques, which are not strictly artificial intelligence, have been around 
for 30 years. There’s all sorts of techniques that we rely on that have been around 
for decades.” Together, their comments demonstrate the diverse range of general 
apperceptions of what these technologies might accomplish, how who develops and 
deploys these technologies may impact healthcare systems (including patients and 
medical professionals), and how popular depictions of and professional experience 
with AI tools contribute to contrasting notions and appraisals of their influence, 
application, and current state of development.
7.  Patient concerns regarding the development, integration, and 
deployment of AI tools in healthcare contexts
Despite varying levels of expertise and general knowledge, the patient inter-
locutors interviewed for this study expressed overlapping concerns regarding the 
development, integration, and deployment of AI tools for oncology and for use 
within healthcare contexts more broadly. Patients regularly articulated three core 
areas of concern regarding issues of regulatory oversight, development and training 
matters, as well as issues of standardization and integration. Together, these com-
mon concerns demonstrate how patients are ingesting existing reports of unin-
tended effects and social risks AI systems across different sectors have resulted in. 
Moreover, they exhibit how patients are envisioning and responding to the potential 
for AI technologies to produce instances of medical error and harm.
17
Toward the Clinic: Understanding Patient Perspectives on AI and Data-Sharing for AI-Driven…
DOI: http://dx.doi.org/10.5772/intechopen.92787
7.1 Patient concerns regarding the need for regulatory oversight
The fulcrum of patient interlocutors’ anxieties concern the need for regula-
tory oversight of AI tools. This issue materialized as a constant chorus for patients 
across nearly every interview. One mode in which this issue was raised was as a 
desire for a “human buffer” or a technical, medical expert between these systems 
and patients. Patients stressed that, beyond issues of efficacy, they were concerned 
that health providers might attempt to thoroughly replace “the human element 
of care” from medical contexts. “Regarding automation and AI techniques” one 
patient explained, “I think it is comforting to have a human around you. Or, to have 
a human be the bridge between robotics and the person, the impersonal screen and 
the person... I think personally it’s still nice to get some human element of care.” To 
ensure the retainment of this experience of care, patients enumerated preferences 
for trained medical experts to explain how these systems work, to remain available 
and present, and to oversee the results that these systems produce in real-time. 
Furthermore, patients fear the possibility of these systems to possess the power of 
executive decision-making. They instead stressed the need to limit the function of 
these systems to auxiliary tools that enable medical professionals and patients to 
make better-informed medical decisions. One patient elaborated: “As for [AI sys-
tems] making decisions, I don’t think it’s the way to go. I think it should be the way 
it’s done now, they give you all the options and the patient can make the decisions. 
Not the machine or anyone else.”
Even more frequently, patient interlocutors articulated the need for regulatory 
agencies and bodies to effectuate heightened oversight, greater legal accountability, 
and guaranteed quality control of these systems as a mandatory precondition to 
ensuring the prevention of medical error. In order to establish the responsible use of 
these systems within medical contexts, patients asserted that these systems cannot 
be introduced into clinical settings without appropriate regulatory safeguards. A 
patient interlocutor articulated this issue as such: “I don’t think it can just be done 
and introduced and used. I think safeguards have got to be put in place and moni-
tored. But who does that? I don’t know.” Other patients voiced misgivings concern-
ing the current lack of regulations because of the existing confusion of when robust 
regulatory schemes will be introduced and how they will operate. Particularly, 
patients are concerned with how regulatory schemes will be organized to arrange 
the necessary flexibility, international collaboration, and enforcement capacity to 
assure both the optimization of these systems and patient safety.
7.2 Patient concerns regarding the facets of AI development
In addition to concerns about the establishment of robust regulatory networks, 
patient interlocutors were also perturbed by unresolved several facets of current 
AI development. Foremost, given AI systems’ reliance on training datasets to 
improve the accuracy and efficiency of its outputs, patients stressed developers 
of AI medical tools are faced with crucial mandates regarding the assemblage of 
training datasets. Patient interlocutors stressed that ensuring regulatory usage and 
patient trust is fundamentally contingent upon developers’ abilities to guarantee 
the accuracy, completeness, and representativeness of their datasets. As one patient 
warned, “forcing learning when the data isn’t there, isn’t the right thing to do.” In 
questioning the potential for this technology to address health disparities or further 
entrench them, some patients raised concerns of how researchers and developers 
are grappling with the limitations of existing health data. Often these data are 
representative of only a small portion of world’s population. Patients fear that if AI 
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systems are trained on inadequate or unrepresentative data, these systems could 
potentially reify medical insights (as well as produce medicines and outcomes) 
with limited efficacy. Emphasizing the need to compile population-representative 
datasets, one patient disclosed: “My other concern with machine learning or AI, it’s 
sort of like that old saying for computers: ‘Garbage in, Garbage out’: to make sure 
you are getting the best training sets from African Americans and Asian Americans 
and Native Americans and not just Americans but all races [across different popula-
tions]... because that’s sort of the big picture. That is the problem with clinical trials 
in the U.S.—you get a bunch of white people! So racial diversity [is needed] and are 
you getting enough participants across all age groups?” To assemble representa-
tive, comprehensive, and accurate datasets, patients further asserted that health 
researchers and AI medical tool developers should be engaging in more collabora-
tive research rather than “working in silos” and aim to include multiple kinds of 
health data including multi-omics data and even non-biological or environmental 
data or multiple data points derived from multiple sources and perimeters. By 
the same token, patients were adamant that AI systems for medical use must be 
able to be updated to integrate new forms of health data. For example, one patient 
mused, that if an AI system functioned to predict health outcomes for patients 
with a certain cancer on a specific treatment protocol, it may run into issues if new 
therapies are discovered and become standard. Given this scenario, he explained, 
“the relevance of the model becomes less significant. So there are issues around 
that. The earlier you are in the interference of data—that is, the ability to learn out-
comes against base data is hugely, hugely relevant.” Correspondingly, patients were 
concerned about the abilities of AI models to be able to be responsive to additional 
information, changes and updates within health contexts. How will that be ensured, 
they asked? And how will the regulatory process account for this given that these 
systems should be retrained often?
Patients also questioned the efficacy of AI development given the relative homo-
geneity of developers. Some patient interlocutors questioned whether emerging 
AI-driven health technologies might only be fully responsive to and efficacious for 
the demographic groups resembling developers. These patients worry that as the tech 
industry is dominated by affluent to middle-class, cis-, white, male developers, the 
questions, issues, and systems developers are currently pursuing might bear the (un)
conscious markings of developers’ particular systemic privileges, interests, politics, 
desires, and bodies [17]. These patients reason that the needs, worldviews, and com-
mitments of those developing technological instruments will inevitably influence how 
these instruments will take shape in the world. Compounded by the troubling homo-
geneity of the tech industry, these patients foresee that these technologies have the 
potential to embody prejudices, unconscious blindspots, or inherent bias that could 
result in “unintended harm” that disproportionately affects the most vulnerable in 
society. Patients stressed the need for “diverse developing teams” who will hold “diver-
sity of viewpoints” and attend to their technologies’ capabilities to reinforce structural 
inequities and unjust psychological biases to produce harm for patients. Their com-
ments are heedful of the extent to which developers are concerned with constructing 
tools that function to oppose apathy, greed, and inequity. As one patient contended: 
“Your tech needs to include and account for everyone or you will create more barriers 
to quality care. It’s about making sure you don’t leave certain patients in the ‘Dark Age’ 
and giving all patients the right treatments for the strongest chance at survival.”
7.3 Patient concerns regarding health system integration and access
Furthermore, patients remain troubled by concerns regarding standardization, 
health system integration, and unequal access to leading-edge medical care. Some 
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patient interlocutors voiced doubts regarding the ability of their current health 
system to integrate and implement the use of these tools in a successful, rapid, and 
straightforward manner. As a result of predicaments stemming from its bureau-
cratic structure and mishaps related to its ability to securely manage health data, 
some U.K. patients held misgivings about the feasibility of the National Health 
Service to manage a transition to widespread, systematic use of cutting-edge, 
AI-driven medical tools. Comparatively, U.S. patients frequently voiced integration 
concerns relating to how the largely for-profit and privatized U.S. healthcare system 
results in unequal access to standard of care and even basic health services. As the 
healthcare landscape in the U.S. remains stunningly rife with inequities, patients 
fear a potential worsening of the existing unequal implementation and access to 
AI-driven systems for medical use. Accordingly, U.S. patients asked: what hospitals 
and medical centers have the resources to launch and integrate this technology for 
patients’ benefits? What patients will be denied access because of factors such as 
geographic location, healthcare provider, hospital availability, and insurance issues? 
How will this further entrench existing healthcare inequities? “While some patients 
might have access [to cutting-edge AI tools for oncology] through tertiary centers 
and university research hospitals, what’s happening at local clinics and hospitals?” 
one U.S. patient asked. “How will standardization play out?” she continued, “We 
have to make sure that people—that everybody—has access to it and that’s not the 
case here.” Another U.S. cancer patient advocate further elaborated: “Everyone 
is thinking it is promising and that it will come our way. My concern is that it is 
broadly accepted to be covered by public systems. We see a lot of disparities in terms 
of what public insurance like Medicare and Medicaid will cover versus what private 
insurance will cover. So my fear is that we are going to have two tiers.” Patient 
interlocutors comprising this interview corpus recognize that issues surrounding 
financial resources and incentives as well as individual health system’s bureaucratic 
and political structures will contribute to the ease or difficulty of systematic inte-
gration of AI tools for medicine. In turn, they reason that this may affect unequal 
access to the most efficacious care and thus, contribute to the further entrenchment 
of existing healthcare inequities.
8.  Understanding patient perceptions regarding data-sharing for AI and 
drug development research
Access to health datasets is a crucial factor in enabling oncology-specific drug 
development and AI systems research. This section examines patient responses and 
concerns regarding sharing their health data for these aforementioned purposes. 
Together, the comments of this sample of cancer patient interlocutors compose an 
opening through which to understand some patients’ perceptions, misconceptions, 
and misgivings regarding sharing their health data. Moreover, their responses 
exhibit variance in both existing knowledge of cancer patients and the extent to 
which they express a desire to be involved in the advancement of proposed AI 
systems for oncology and oncology drug development vis-a-vis data-sharing.
8.1 Data-sharing and research participation: concerns and caveats
Virtually all of the cancer patients interviewed for this study expressed both 
general enthusiasm and an overall willingness to be involved in oncology drug 
development and oncology AI tool advancement in some capacity. Furthermore, 
nearly 22% of the patients comprising the interview corpus indicated that they 
trust the regulatory schemes and ethical parameters that currently guide public and 
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private entities involved in research enough to be willing to share their medical data 
for research purposes without any additional conditions or specific requests beyond 
these existing mandates. The potential for various issues pertaining to data security, 
storage, targeted surveillance, as well as risks of data re-identification and discrimi-
nation, did not inhibit these patients’ desire to contribute to oncology drug and AI 
development research. In their view, these potential complications did not present 
an undue risk to them given the existing frameworks of ethical and legal protections 
regarding research.
Nevertheless, the remaining portion of patient interlocutors held concerns and 
caveats potent enough to potentially prevent them from agreeing to participate in 
research. These patients presented a series of considerations that they specifically 
want corporate researchers to address in order for them to feel comfortable enough 
to agree to contribute health data for a private entities’ (e.g., pharmaceutical or 
biotech companies) efforts to conduct research regardless of their affiliations with 
medical research institutes or university research centers. Notably, however, when 
presented with a hypothetical scenario in which a university or medical research 
institute was conducting research without corporate collaboration (exclusive of 
funding) nearly all patients were willing to offer their medical data without any 
major caveats although a small number insisted that their willingness to share their 
data would be affected by corporate sponsorship in this scenario.
8.2 Concerns regarding data security and patient privacy
Most commonly, patient interlocutors declared that their primary concern with 
respect to sharing medical data for research purposes pertains to issues of data 
security and privacy. Despite current legal and ethical standards mandating the 
anonymization of medical data for research, patients voiced that keeping their data 
anonymized and their privacy secure remains their top priority and issue of con-
cern. Still, several of these patients admitted that if they were assured that their data 
would be kept anonymized and would be securely stored with respect to current 
industry and legal standards, they would be willing to participate in research. While 
a small number of patients expressed doubts as to whether their healthcare provider 
(i.e., the National Health Service) can effectively keep patients’ health data secure 
from hackers and data leaks, the majority of patients comprising this interview 
sample conceded that they had little to no knowledge of how their health data might 
be stored, kept secure, or circulated beyond their medical provider’s institution.
8.3  Lack of knowledge about legal mandates and fears of insurance 
complications
Many patients also disclosed that they were unsure of the dictates that ethical 
review boards and legal frameworks impose on researchers working with health 
data. While all of the U.S. patients interviewed were at least aware of the federal leg-
islation known as the Health Insurance Portability and Accountability Act or HIPPA 
(if not also other federal statutes such as GINA or relevant state laws), in contrast, 
U.K. patients, with the exception of those whose profession involves health data-
handling, disclosed that they typically unaware of U.K. statutes regarding health 
data protections to any degree of notable detail. Regardless of whether this igno-
rance stems from a lack of interest, from trust in the National Health Service to fully 
comply with the mandates of legal ordinances, or some other reason, both U.K. 
patients and U.S. patients alike indicated a concern that current legal frameworks 
are likely too lax in ensuring the protection of patients’ ability to access healthcare 
via private insurance. This was the second most frequently cited concern related to 
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health data-sharing and research participation across the interview corpus. “I am 
deeply concerned this data will make their way to insurance companies and affect 
premiums,” one patient asserted. In the event of a data breach or a scenario in which 
data mining allowed health insurance companies to have access to individuals’ 
health data subsequent to sharing their medical data for research purposes, patients 
questioned whether current law is robust enough to prohibit health insurance 
companies from obtaining their medical data for purposes of denying them cover-
age or limiting their access to coverage through higher fees for coverage based on 
data originally shared for research purposes.
8.4 Understanding other demands for securing consent
Beyond issues of data security, patients consistently related several other factors 
that would influence their decision to share medical data with a corporate entity for 
AI and drug development research related to oncology. Most frequently, patients 
expressed that they would be willing to share their data with companies for these 
purposes provided their research was explained to them in full and that they agreed 
with the ethical imperatives of the study and corporation more broadly. In this vein, 
patients were consistent in insisting that they wanted to know: (1) the research 
objectives of a potential study, (2) if the study posed any risks or potential for harm. 
To a slightly less degree patients asserted that they would also want to be informed 
about where their data would be stored once shared and who it would be handled 
by, who would own the data once it is shared for research, if their data to kept for 
future use or circulated for use in other studies, how the study was to be funded and 
executed, and how the corporate entity manages their profit motives with ethical 
mandates. Moreover, if provided with all this information, some patients explained 
that they would then only be willing to share their data if the company designed 
their research with the imperative to benefit as many cancer patients as possible. 
For instance, two patients related that if a pharmaceutical company was aiming to 
conduct research for a drug that would have only a minimal effect on patients’ well-
being and outcomes such as only be able to “prolong life for two months” based on 
“the need for profit” then they would not be interested in sharing their health data. 
“Big Pharma,” another patient emphasized, “is difficult to trust.” Others noted that 
they would want to gather more information about how the hypothetical company 
may or may not be engaged in depriving some patients of necessary treatments. 
One patient explained that if a company had a history of using patients’ data to help 
create drugs in order to then charge exorbitant prices that placed the drug out of 
reach for a majority of patients, they would not be willing to share their data to aid 
a company in their research. Still, two patients conceded that the future prospect 
of production of generics in this scenario would satisfy them enough to want to 
share their data. In addition, some patient interlocutors asserted their desire to 
be updated about the status of the research and its potential outcomes. Likewise, 
patients wanted to be assured that if researchers handling their data were to find 
something medically concerning or relevant to their future health status (e.g., a 
genetic predisposition for a disease) that they would be notified by the research 
body although some admitted that they were unsure as to how this would be accom-
plished given de-identification of the data.
8.5  Concerns regarding corporate ethics and the potential for targeted 
advertising
Moreover, patients insisted that additional regulatory safeguards are needed 
both in the U.S. and in the U.K. to protect patients participating in research not just 
Artificial Intelligence in Oncology Drug Discovery and Development
22
from healthcare coverage issues, but also from the potential for corporate surveil-
lance and targeted advertising based on their medical data. Specifically, patients 
indicated that they believe that sharing their health data with entities beyond their 
healthcare provider and health insurer could potentially expose them to further 
and more intrusive corporate surveillance and targeted marketing. Although the 
inherent profit motives of private corporations admittedly troubled some patients, 
this factor and the potential of targeted marketing alone did not compel any patient 
interlocutors to declare that they would refuse to share their medical data based 
on these factors. Rather, patients related that they would take a “holistic” view of: 
the company, its research aims, the procedures and mechanisms of the study, and 
why and how a company might ask participants to transfer ownership of their data 
and further circulate it beyond the individual study. “Before I share my data,” one 
patient concluded, “I would really need to interrogate the company and its aims.”
Critically, patients widely differed in their insistence of how data security and 
related issues might be pertinent to their decision to participate in research for 
oncology drug development and AI One U.S.-based patient advocate who primar-
ily works with low-income cancer patients offered an explanation to suggest the 
variance with which patients stated these issues as relevant matters of concern. 
She contended that patients’ awareness of and inclinations to voice such concerns 
regarding data security and privacy are contingent upon their health status, 
resources, and level of education. She explained, “I don’t know how much patients 
know about the extent to which their health data is being shared. I don’t think I do 
either but to the extent that I do know...gosh, I think ‘Wow, I didn’t know that!’ So I 
don’t think most people know...Sometimes with advocates may be higher resourced 
or have come through [their treatments] and are now stable because in the thick of 
it I don’t hear patients being worried about [issues related to medical data-sharing] 
during the thick of treatment. Also, we have many clients who are less savvy about 
the system, and that is, lower resourced here, generally. So I haven’t heard a word 
about it. They are concerned with their personal privacy when it comes to their 
social security number, their immigration status, et cetera but as to whether they 
are concerned with their local CVS selling their data out? I don’t think they are 
concerned with that. I think that concern is a higher Maslow level than for instance, 
‘I’m in treatment and I gotta feed my family.’” In this advocate’s view, patients’ likeli-
hood to be concerned about the aforementioned issues of data ownership, security, 
data brokerage, threats to insurance coverage, and targeted corporate advertising 
necessitated a health status, insurance status, and an educational background that 
would allow them to consider such issues as sufficiently critical and indeed, the data 
collected by the author did not seem to dispute this view.
8.6  Genetic data-sharing: fears of discrimination and lack of knowledge  
and value
A smaller number of patients related they feared that in the event of a health 
data breach, or of medical data circulation subsequent to a private entity’s transfer-
ence of patient data to health data brokers following research participation, some 
individuals might be subjected to discrimination or stigma based on their health-
care status, data, or medical history. Patients were particularly concerned with 
discrimination and corporate surveillance with respect to genetic data. Although 
patients often insisted that they believed genomics “provides an additional path for 
predicting the cause of cancer,” that it will potentially “improve personalized treat-
ment,” and that “generally speaking, they see few negatives to [genomics] research,” 
many related that they remained apprehensive of what social effects the study of 
such data might entail and communicated fears related to the stigma of medical 
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genomics. For instance, some held fears of how genetic studies might embolden 
some researchers to take up “social genomics studies” reminiscent of the twentieth-
century eugenics and pseudoscientific approaches to genetics. In further explaining 
these qualms, patients cited the potential for discrimination related to genetic pre-
dispositions, STI or HIV/AIDS status, or mental health histories. As a result, a large 
portion of patients indicated that as legal protections against such ramifications 
are, by their estimations, weak or fail to account for contemporary use, patients 
may demand additional assurances from private entities engaged in health research 
that if they were to participate in research by sharing their medical data with them, 
their data would be secured to the highest possible standard and sufficiently de-
identified. As one patient explained, “As as it can be de-identified with confidence, 
then data leaks may be less harmful.” Some patients raised other concerns about the 
current lack of education regarding genomics and cancer patients, corporate actors, 
and oncologists possess. One patient contended: “I think the field is still early. I am 
concerned about commercial tests that may not be looking at the same genes and 
may give different results. Genetic counselors are a must!” Patients possessing these 
concerns were adamant that genetic data and genomics research needs to be coupled 
with educational initiatives and expert roles to explain results, consent procedures, 
and possible harm.
8.7 Issues of financial compensation, benefit-sharing, and medical inclusion
Finally, although most of the patients comprising the interview corpus were 
willing to share their health data for research without the prospect of financial com-
pensation or benefit-sharing possibilities, approximately 15% of the interviewees 
(both U.S. and U.K. patients) stressed that these issues would greatly influence their 
decision to share their health data with a private entity. This issue was particularly 
important for patients who were currently undergoing treatment. One patient, 
a mother in her early forties currently undergoing treatment for a rare cancer 
type, explained her interest in financial compensation and other benefit-sharing 
as well as how it would affect their decision to participate in private research: 
“Compensation is nice but I suppose if they can’t compensate and then can’t use the 
data, I would rather them be using the data if it’s going to be for the greater good 
and improving medicines and technology. I suppose it would be nice to know what 
they are working towards. So, in turn, they share: ‘This is what we are trying to 
achieve.’ But I sort of assume that if they use your data and have anonymized it by 
the time they do the study there’s really no way of them being able to come back and 
say, ‘This is what we’ve done with your data.’ In a case like with [the pharmaceutical 
company who makes a drug I need access to in order to attain a higher chance at 
survival], if they used your data to create a drug and then sell it for a sky-high price 
that you can’t afford, I think that’s wrong in a way. Why should they sell it at this 
sky-high price if they’ve used this data which has come to them as a free resource? 
Why is that fair? I suppose I’ve not really thought it through to that extent when I’ve 
given permission [before however] because I just think if this is research, it may 
possibly help me or help someone else in the future. [So] I probably would still want 
them to have the data. But maybe there should be other controls to stop them charg-
ing the Earth! Just making these drugs and saying, ‘these drugs are really amazing 
but you can’t have them because they are ridiculously expensive...We’ve made these 
drugs from your data which we have gathered and now we will sell them for ‘x’ 
amount.’ So yeah I suppose we would want some financial gain if you are going to be 
passing your information off to these companies...I would want the NHS [National 
Health Service] or say, Cancer Research UK, or someone like that just to use my data 
but maybe it is a bit different if you are talking about a big pharmaceutical company 
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that’s making billions of dollars or whatever...They can afford to compensate you...
and yeah there’s generics and I get that. I know that they will come out with gener-
ics for [the drug I need] eventually, but that’s too late for me. I need it now.” This 
patient interlocutor’s explanation of their conditions for medical data-sharing for 
research participation offers a sense of how patients currently undergoing treat-
ment are conceptualizing the issue of sharing their data and how they wish to 
benefit in the event of doing so.
In contrast to this patient’s understanding of the value of their medical data and 
sense of how it might be valuable for other actors, many patients expressed puzzle-
ment and apprehension with regard to how their data might hold future and current 
value. For example, one patient related: “My major concern is that there’s not 
enough knowledge to really benefit [for and as a patient currently undergoing treat-
ment] from shar[ing] this health data [including genetic data, with researchers]. I 
really wish it could accelerate and that we could use AI to guide the treatments but 
there’s not enough treatments out there to make a massive difference. I hope that 
it will progress soon...but today I don’t really know what you could do with this 
data that would impact your life in any way.” In addition to patients’ doubts that 
participating in research would have a significant impact on the health outcomes 
of current patients, other patients were confused as to how, in the event of a data 
breach, their health data information might be of value to others including hackers, 
government agencies, or corporate entities. “Why would someone want to hack 
into a researcher’s storage system and take my data” and “why would someone want 
to re-identify my data?,” some patients questioned. One patient insisted that this 
would have no bearing on a decision to participate in research: “But why someone 
want to do it? I don’t really see any reason. So no, it [is not and] wouldn’t be a worry 
for me.”
In addition to issues of financial compensation, some patients noted that issues 
of consent regarding medical data-sharing were of critical importance to influenc-
ing how likely they are to share their data with researchers for AI advancement 
and drug development. As several patients were insistent that medical inclusion of 
diverse populations in research must be a priority, some asserted that they would be 
unwilling to share their health data with researchers if they did not make the inter-
related issues of patient trust, efficacy, and medical inclusion key to their research. 
To this end, these patients wanted researchers to prioritize building relationships 
to recruit diverse populations for their studies, offer educational initiative to help 
equip potential participants with sufficient knowledge regarding what impacts and 
effects their participation might result in, and be committed to sharing resources 
and the benefits of “lower-resourced” populations. Only a demonstration of such 
commitments could impel these patients to want to share their data for research.
9.  Patient-centered approaches to building frameworks of trust and 
accountability
This section examines patient-centered recommendations and proposals for 
ensuring patient trust, participation, and safety pertinent to increasing the devel-
opment and clinical use of AI systems for oncology. Building on cancer patients’ 
concerns, this section highlights three major arenas for cultivating frameworks of 
trust and accountability crucial to advancing these systems and ushering them into 
clinical settings. Drawing from the qualitative data produced by this study in addi-
tion to the insights of other researchers, these three imperative arenas in need of 
reinforcement include: Building Knowledge and Redressing Consent and Resource 
Sharing; Addressing Health Inequities for AI Accountability; and, Promoting and 
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Establishing Additional Safeguards. Strengthening patient support, understanding, 
and participation in AI-related oncology drug development requires robust, varied 
responses to these three interrelated arenas of concern from a multitude of relevant 
actors. This section provides an overview that attempts to synthesize the attitudes, 
positions, and actions stakeholders can undertake to broadly ensure accountability, 
equity, and patient trust and participation with regard to these systems.
9.1  Navigating patient participation and trust: building knowledge, redressing 
consent, and sharing resources
Educational initiatives remain a critical aspect to earning trust and maintaining 
accountability within AI-oncology related research endeavors. Establishing truly 
informed consent requires equipping cancer patients, cancer patient advocates, and 
oncology care providers with the necessary knowledge to stay informed and alert 
about how these systems operate, how they are designed and trained, what ramifi-
cations might ensue as a result of their implementation. Cancer patient advocates 
are particularly vocal in stressing the importance of giving patients all necessary 
information required in order to understand what potential limitations or risks such 
systems may incur. They further assert the need for a collaborative approach to both 
building patient knowledge and to assessing how potential harms and complica-
tions are to be addressed. They believe that collaboratively produced and executed 
educational initiatives will foster support among the general patient populace for 
public and private investments in both AI development as well as for the infrastruc-
tural adjustments within their use may necessitate. Advocates and oncologists alike 
contend that patients often remain ignorant of the options for medical coverage and 
care available to them, particularly with respect to clinical trials and other forms of 
research involvement. This lack of education not only comprises one barrier to par-
ticipating in oncology-related research and drug development studies, but also may 
furthermore preclude patients from receiving the highest quality of care at their 
disposal. Additional knowledge regarding research endeavors and their potential 
benefits may encourage patients, many of whom profess to be open to engaging in 
research, to participate in AI-driven oncology drug development studies.
Indeed, many cancer patients, including the interlocutors who informed this 
study, actively assert their desire to learn more about the AI-driven systems that 
have the potential to considerably impact their treatment from trustworthy sources. 
Patient advocates reason that given the aforementioned demands on patients as 
well as the nature of clinical care, more advocates, researchers, and clinicians must 
be trained in how these systems operate and in how they might affect patients in 
order to equip them with the necessary expertise for helping patients navigate 
and assess the potential ramifications that these technologies may have on their 
treatment. Undeniably, more initiatives need to be established to educate patients 
in how machine learning-driven systems operate, what their levels of efficacy are, 
and what greater social effects they might precipitate. Such educational initiatives 
would serve as a crucial first step in assisting current, former, and future patients 
in understanding what crucial arenas can be acted upon to ensure that patients 
receive the quality of care they deserve. These arenas might include, for example, 
participating in relevant research or reinforcing support for policies that attempt 
to carve out how issues of liability will enfold in the face of medical error due to AI 
system usage. As stated earlier, such educational endeavors may hold higher stakes 
and greater challenges for patients with “limited access to high quality clinical care, 
limited health literacy, earned mistrust of medical providers, and those individuals 
who may be exposed to interpersonal and institutional racism and other discrimi-
nation in their healthcare encounters” [14].
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Nevertheless, it remains important to consider how matters of securing consent 
and research participation extend far beyond merely bolstering educational initia-
tives for patients. For instance, too often issues pertaining to refusal of consent 
and slim participation are framed as the consequence of ingrained beliefs that 
stem from cultural beliefs rather than as rational stances toward the injustices of 
biomedical research from beget from the nexus of material inequities and historical 
oppressions. Against the myopia of cultural determinism, researchers of technology 
and medicine contend that patients’ (un)willingness to participate in research must 
be appropriately contextualized as complex responses to biomedicine in socially 
stratified societies. Ruha Benjamin frames such arguments in the following terms: 
“If we understand trust and distrust not simply as individual or cultural predisposi-
tions that are ‘held’ by some and not by others, but rather as outgrowths of social 
relationships that are produced through the allocation of material resources and 
symbolic power, then we see that techniques for cultivating relationships hinge on 
redistributing and refashioning those, respectively” [18].
Exemplifying the limitations engendered by material inequities, clinical trials fre-
quently fail to recruit people of color and other marginalized people. This fact holds 
further significance as research conducted by the U.S. Census Bureau predicts that 
the white population in the U.S. will fall below 50% by 2045. In conducting interview 
work, it was typical to hear patient advocates and medical professionals bemoan 
how clinical trials and other research endeavors struggled to recruit “diverse” 
patient groups for their studies. Beyond educational matters, advocates, clinicians, 
and cancer nonprofit directors frequently framed the issue of participation as one 
dominated by cultural inclinations (some groups are like ‘x’—‘x,’ in this case, being a 
list of static traits or stereotypes of racial groups) rather than as dispositions toward 
structural inequities. Through cogent research that examines how clinicians’ “‘ideas 
about [their patients’ ‘cultures’] contribute to health disparities,” anthropologist 
Khiara Bridges contends that “cultural stereotypes and beliefs in the way people 
from certain cultures ‘just are’ can be dangerous—and just as racist—as racism” [19]. 
Demonstrably, cultural determinism can result in deleterious health outcomes.
To combat this, Benjamin argues that it is necessary for medical researchers and 
health professionals to turn “away from a fixation with distrust and towards the 
problem of institutional trustworthiness” [18]. This logical turn refuses to heap 
blame, stigma, or tidy labels of ignorance upon marginalized populations whom 
medical researchers find it difficult to recruit for studies. Instead, it asks research-
ers to assume a self-reflexive approach to their work and recruitment efforts and 
compels them to question how their institution, research body, and associates 
can be accountable to marginalized populations possessing an earned distrust of 
medical intrusion whom researchers aim to include in medical studies. In advancing 
the logical turn from a narrow fixation on issues of patient distrust to the broader 
problem of institutional trustworthiness, health practitioners, tech developers, and 
medical researchers may begin to fruitfully rectify inequalities rather than repro-
duce stale, cultural deterministic, and circumlocutory narratives of why “subordi-
nate groups remain elusive to researchers” [19].
Ethicists and researchers similarly stress the need to rethink current regulations for 
securing consent for biomedical research. They advocate for a shift from the para-
digms of one-time consent to frameworks of accountability that attend to participants’ 
evolving concerns and adhere to ongoing commitments of responsible use of partici-
pant samples. They argue that as political surroundings, public opinion, the type of 
information collected, and the application of this data necessarily shifts, researchers 
must build responsive systems of consent. Consent practices, they argue, must not only 
integrate ongoing assessments of the risks and implications of their research but also 
frequent monitoring of patient attitudes, beliefs, and perspectives.
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Ethicists assert that more needs to be done to guarantee reciprocity or ensure 
that participants, not just researchers and their affiliated institutions and fund-
ing bodies, are also benefiting from the research. This begins with a willingness 
to address historical injustices that have contributed to the mistrust that certain 
groups continue to hold with respect to biomedical research. For some, distributing 
broad benefits in genetics and genomics research involves making research and 
research instruments publicly available so that they are not tethered to the limited 
access that often characterizes commercial arrangements. Ethicists also explain 
that research organizations can engage in capacity-building in which more richly 
resourced research organizations collaborate and share resources with “lower 
resourced” organizations and community participants.
As ethicists continue to advocate for benefit-sharing in research through 
endeavors like capacity-building and commitments to engaging in open source 
and public domain initiatives, they also advocate for the redressal of the politics1 
of recruitment itself. As anthropologist Cori Hayden argues “scientific knowledge 
does not simply represent (in the sense of depict) ‘nature,’ but it also represents”... 
(in the political sense) the ‘social interests’ of the people and institutions that have 
become wrapped up in its production” [21]. Following Hayden’s affirmation of the 
“coproduction” of all scientific endeavors, Benjamin advocates for attending to 
“informed refusal” as “a necessary corollary to informed consent—one that extends 
the bioethical parameters of the latter into a broader social field concerned not only 
with what is right, but also with the political and social rights of those who engage 
technoscience as research subjects and tissue donors” [18]. Benjamin explains that 
“the notion of informed consent—although developed to protect the rights and 
autonomy of individuals to accept or refuse participation in research—implicitly 
links the transmission of information to the granting of permission; in conse-
quence, “the request to consent can be interpreted as guidance to consent” [18]. 
Juxtaposing “informed” and “refusal” thereby acts a signal of necessary humility 
that recalls individuals’ right to refuse participation and recognizes a paradigm in 
which refusal derives from an educated stance.
It is not enough to recognize that educational initiatives have the capacity to 
contribute to bolstering research endeavors. Rather, scholars of science and tech-
nology and medicine stress how “what matters is not only who is in the room and 
the intentions of those gathered, but also the structures of participation, modes 
of inclusion, and assumptions about what forms of knowledge and expression are 
valid and relevant” [18]. One U.S. based patient advocate incisively summarized 
these issues surrounding recruitment, knowledge-building, and participation.
“A researcher wants their research to be successful so they write their hypothesis 
and their aims to prove it. If a researcher has a skewed view about a group, I have 
seen that they write their study skewed that way. When researchers are doing some-
thing where they want to get groups in, I think they have to be honest first. A lot of 
the times the researchers don’t look like the community. So you can’t walk into the 
community and not be willing to hear their feelings. It’s important for communities 
of color to be in research. Part of that problem of not knowing how things affect 
African Americans, Asians, Latinos, and Native Americans is because they are not 
involved. But they also don’t have a reason to trust. So like I said to someone who 
was trying to conduct a research project, she said, ‘Well I don’t look like them’ and I 
said, ‘Then you say that.’ You don’t walk in there and pretend that the people looking 
1 Politics, invoked here, does not solely refer to the mechanisms of electoral issues concerning political 
candidates or parties. Rather, it extends to the “collective social activity”—“public and private, formal 
and informal, in all human groups, institutions and societies” which affects who gets what, when, and 
how [20].
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at you do not see that you are a white woman. You admit it. ‘I don’t look like you. I 
know that. And here’s where my heart lies. I want to hear what you are thinking’. 
Because at least then you look as though you are there for the right reason and you 
are not looking to skate around the elephant in the room. Because it is about build-
ing relationships. You want someone to participate in your study. You know that 
people of color need to participate and particularly now that they are talking about 
precision medicine and personalized care. If people of color don’t participate in that 
then what will they know about us? They won’t know anything. We will be in the 
dark age because we are not participating. Although someone came and talked to us 
and said ‘Getting people to participate in clinical trials even in the white commu-
nity is low. It’s lower with people of color.’ but there is something that you already 
know: tell the truth. [laughs] Say, ‘I want to do this research.’ But I feel like with 
researchers if it’s with people of color that you don’t know and that you have your 
implicit biased conceptions that were passed down or told to you, you don’t want 
to work with those groups. Like ‘Oh I don’t want to work with that group because 
they are this.’ When actually, you don’t know that. When actually you could make a 
difference and be noticed where others weren’t by stepping out and taking that risk 
because we already know as medicine is moving in this direction of personalized 
care, that other populations need to be considered. But you gotta be honest and you 
gotta figure out how to get them involved and getting them involved is sitting down 
and talking with them. Not saying ‘hey I want to do this research I am going to come 
into your community and I am going to use you and then I am going to disappear.’ 
But making a commitment to come back to the community and share what you 
learned. When I worked for American Cancer Society and was in San Francisco... I 
remember Black people [from the Bay View/Hunter’s Point neighborhood] talking 
about how many researchers showed up and came in, did a research study, got their 
data and took off and never came back. Well that group never wanted to see another 
researcher, ‘all they wanted to do was use us.’ You have to change it. And that, to 
me, means that you are willing to sit there and hear the difficult stuff...if there isn’t 
a hospital, if they have no way of getting the standard things needed, then how do 
you partner with other people?...So, researchers,...find out what is out there and 
available. Because there has to be a way to work around [institutional limitations 
like funding caps]. Saying ‘ok you are only going to fund this but I found these 
other community organizations and clinics, how can we work with them to try to 
bring the community you are working with back a solution?’ Instead of stopping 
and saying this is too hard and this is why I don’t work with this community. You 
problem solve.”
In addition to building patient knowledge concerning: medical technological 
advancements, research endeavors, the ramifications of technological interven-
tions, science and technology studies scholars, biotechnology researchers, and 
patient advocates maintain that health inequities must be robustly addressed. 
With regard to making health technologies inclusive rather than exclusionary, 
patient advocates advise developers and medical researchers to seek out and col-
laborate with communities of color and other socially marginalized groups. They 
encourage conducting research and creating tech that focuses on and addresses 
the needs of vulnerable groups. A crucial aspect of such a venture, they assert, 
involves: building relationships and collaborative problem solving with these 
interlocutors to ensure that needs of these groups (such as basic access to standard 
treatment options) as well as the analyst’s research goals are met. Patient advocates 
stress that those willing to be pioneering in this regard will be hailed as vanguards 
and more importantly, are more likely to be recognized by myriad patient groups 
as worthy of trust.
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9.2  Addressing and preventing the entrenchment of existing health inequities 
via AI tools
Amid the excitement for the potential medical insights machine learning and 
other AI systems might enable stands an increasingly emphatic chorus of experts 
urging both the developers of these systems and health specialists to ensure that 
these systems work to mitigate rather than entrench existing healthcare inequities.
Technology experts and critical algorithm studies scholars implore that we 
evaluate how these AI models—which increasingly manage and organize our lives—
are far from neutral or objective tools. Rather, as mathematician Cathy O’Neil 
asserts, we must soberly weigh how these instruments are demonstrably encoded 
with human prejudice, misunderstanding, and bias [22]. One reason for this lies in 
the fact that these systems and the insights they generate are fundamentally reliant 
on training data sets composed of existing reference data. Conveying the fallibility 
of the data-driven paradigm within a different sector, in 2018 Amazon reported 
that the company was forced to discontinue its AI hiring and recruitment system 
because it discriminated against women applicants. Amazon’s recruiting tool relied 
on resumes submitted to the company over the previous 10 years—the majority of 
which came from men. Accordingly, these reference data organized the algorithm 
to give preference to male applicants and to screen out women applicants vis-a-vis 
subtle cues in their resumes such as experience in a women’s organization or educa-
tion at a women’s college [23].
In another example beyond medicine, in 2016, investigative journalists uncov-
ered how predictive criminal risk assessment algorithms—software used by US 
courts to predict how likely a person is to commit a crime in the future and relay 
a recommendation for sentencing to a presiding judge—are prejudiced toward 
people of color as they consistently recommend stronger sentencing for Black and 
Latinx people [24]. Scholars, among them Ruha Benjamin and Safiya Noble, and 
investigative journalists such as Julia Angwin continue to scrutinize the ramifica-
tions of integrating AI systems across a multitude of disparate realms among them: 
housing, finance, news media, welfare eligibility, social media platforms, popular 
search engines, and healthcare. Their research confirms that AI systems possess the 
capacity to exacerbate existing social inequities.
As the preponderance of data-driven solutions becomes the norm for healthcare 
specifically, experts demand that we address how these tools can compound exist-
ing disparities in healthcare outcomes. One step toward this remediation, research-
ers assert, involves educating healthcare providers and developers to ensure they 
sufficiently comprehend how systemic inequities affect individual health. A robust 
understanding of the causes, consequences, and modes in which health inequities 
exist not only affords medical specialists and health tech developers a sense of what 
research and technological solution need to be prioritized to address injustices, 
but it can also coincide with a self-reflexive method of medical engagement. In 
other words, knowing how, why, and what health inequities exist, can allow one to 
approach health interventions with a heightened awareness of the imbrications and 
the potentially far-reaching implications of their actions and mediations. It would 
allow one a crucial frame of reference to question how their instruments and actions 
might be a catalyst for perpetuating social harm. Many argue that this knowledge is 
a necessary, fundamental, initial step toward remediating health injustice.
Dr. Tina K. Sacks, a medical sociologist who investigates how race and gender 
impact health outcomes and a proponent of this kind of knowledge building, advo-
cates for a structural approach to understanding health inequities. Sacks asserts: 
“Although the dominant paradigm in the United States emphasizes individual 
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choice and responsibility, the empirical evidence indicates that our neighborhoods, 
schools, jobs, and other factors of day-to-day life shape individual and population 
health” [25]. Similarly, medical historian John Hoberman analyzes how the histori-
cal legacy of racialized thinking is reflected in the contemporary U.S. medical estab-
lishment by focusing on how physician racism contributes to health disparities. 
Hoberman’s research suggests that medical providers rely on false beliefs rooted in 
racial essentialism—such as the pernicious myth of so-called Black “hardiness”—to 
determine diagnosis and treatment for Black patients [25]. In addition to racial and 
gendered oppression, in the past several decades, researchers have demonstrated 
that health and well-being strongly correlate with socioeconomic status. Sacks 
summarizes: “One of the most important systemic inequalities is unequal access to 
income and wealth, which may lead to poor health behaviors, chronic conditions, 
and disease” [25].
The findings of the Institute of Medicine’s2 seminal study of the causes and 
ramifications of pervasive healthcare disparities in the US and the volume of 
research it prompted, found physician bias, whether conscious or unconscious, 
to be a crucial factor in the production of disproportionate healthcare outcomes. 
Subsequent empirical studies suggest that people of color and ethnic minorities, 
women, and other people who occupy vulnerable social positions are most suscep-
tible to the noxious consequences of bias and stereotyping. Sacks further flags that 
“numerous studies have documented that healthcare providers are unconsciously or 
unintentionally biased against members of marginalized groups, which ultimately 
leads to difference in treatment across multiple domains (i.e., speciality care, pain 
management, mental health services, etc.)” [25].
Myriad experts assert that it is imperative that we are cognizant and considerate 
of how social inequities are embedded into the health data upon which AI systems 
are built. Due to design and optimization constraints, training datasets primarily 
utilize the health data profiles of those who can afford and have access to long-
term, continuous healthcare as opposed to those who have limited access to care, 
discontinuous care, or fragmented records. Moreover, data gathered via clinical 
trials have long been known to be unrepresentative of the US population. Clinical 
trials routinely fail to recruit people of color and other marginalized people. 
Recently, investigative journalists at ProPublica reported that Black Americans, 
Native Americans, and other Americans of color are steeply under-represented in 
clinical trials for cancer drugs—even when the type of cancer disproportionately 
affects them [26]. This has translated to cancer treatments that are least effective 
for the population most afflicted by the disease. Critically, people of color continue 
to have disproportionately higher incidence and mortality rates for kidney, breast, 
prostate, and other cancers [14]. Likewise, AI tools designed to detect skin cancer 
have proven less adept at diagnosing skin cancer in Black and brown patients than 
white patients [5]. While people with fair skin have the highest incidence rates for 
skin cancer—the most prevalent human malignancy—the mortality rate for people 
with darker skin such as African Americans is considerably higher. Eric Topol 
contends that this is especially noteworthy for genomic studies driven by machine 
learning techniques: “First, people of European Ancestry compose most or all of the 
subjects in large cohort studies, which means that, second, they are of limited value 
to most people, as so much of genomics of disease and health is ancestry specific” 
[5]. Prioritizing health equity would not only result in more robust scientific and 
medical knowledge, but would also constitute a step toward engendering quality 
healthcare for all.
2 Now known as the National Academy of Medicine.
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Increasingly, health researchers such as Sacks and Jonathan Metzl propose 
efforts toward remediating health inequities that center on structural competency. 
They advocate for well-researched efforts at the institutional level that aim to 
address the enduring effects of historical oppression. For example, Sacks explains 
that structural competency involves moving beyond obfuscating framings of racism 
as a troubled American past or simply an individual failing of “bad” or “unedu-
cated” people. Instead, structural competency demands that we analyze how racism 
constitutes structural phenomenon embedded and reproduced in US institutions 
such as medical schools and healthcare settings [25].
Technology developers and data scientists, moreover, must also be involved in 
building structural competency across the institutions they navigate to produce 
more robust, just, and effective technological instruments. Data scientist Ben 
Green affirms that “by developing tools that inform, influence, impact important 
social or political decisions—who receives a job offer, what news people see, where 
police patrol—data scientists play an increasingly important role in constructing 
society” [20]. In consequence, Green argues that it is imperative that data scien-
tists move away from conceptions of technological instruments as simple tools 
that can “be designed to have good or bad outcomes” and instead recognize how 
the technologies they are developing “play a vital role in producing the social and 
political conditions of the human experience” [20]. By this logic, Green asserts that 
data scientists must also come to recognize themselves as political actors engaged 
in the “process of negotiating competing perspectives, goals, and values” rather 
than as neutral researchers merely coding away in their offices [20]. The decisions 
data scientists make and responsibilities they hold “cannot be reduced to a narrow 
professional ethics that lacks normative weight and supposes that, with some reflec-
tion, data scientists will make the ‘right’ decisions that lead to ‘good technology’” 
[20]. As “technology embeds politics and shapes social outcomes,” a position of 
neutrality remains an “unachievable goal” Green contends, as first, “it is impossible 
to engage in science and politics without being influenced by one’s background, 
values, and interests [20]. Second, striving to be neutral is not itself a politically 
neutral position—it is a fundamentally conservative one” as such a stance functions 
to maintain a radically inequitable status quo. Correspondingly, Green debunks the 
logic of the common tech refrain: “‘we shouldn’t let the perfect be in the enemy of 
the good’” [20]. Green highlights that data science lacks any theories or coherent 
discourse “regarding what ‘perfect’ and ‘good’ actually entail” and furthermore, 
“fails to articulate how data science should navigate the relationship” between 
the two notions; instead, such a claim “takes for granted that technology-centric, 
incremental reforms is an appropriate strategy for social progress” [20]. Green 
then points to the example of criminal risk assessment algorithms; “even if they can 
be designed not to have racial bias,” he argues, their deployment can “perpetuate 
injustice by hindering more systemic reforms of the criminal justice system” [20]. 
While recognizing that data science is capable of improving society, in Green’s 
assessment, a structurally competent approach demands that algorithmic and data 
science solutions be “evaluated against alternative reforms as just one of many 
options rather than evaluated merely against the status quo as the only possible 
reform” [20]. There should not be a starting presumption that machine learning (or 
any other type of reform provides an appropriate solution for every problem...data 
science reforms tend to (implicitly if not explicitly) assert that the precise means by 
which decisions are made is the only variable worth altering. There may be situ-
ations in which this assumption is correct, but it should not be made or accepted 
lightly, without interrogation and deliberation” [20].
Furthermore, patients and patient advocates recommend cultivating patient 
and health practitioner education in relation to developments in technology and 
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healthcare as a significant step toward getting patients the right treatment involves 
informing them of their treatment options and of any potential consequences and 
side effects. This mandates that medical care providers be sufficiently educated to 
guide patients and that education materials are deliberately designed to be acces-
sible and easily comprehendible (e.g., offering treatment pamphlets in several 
languages rather than solely in the dominant language). For patient advocates, 
these three recommendations are critically imbricated in one another. One patient 
advocate succinctly questioned: “How am I supposed to educate a patient about a 
new treatment or drug they won’t have access to it?” Experts across the realms of 
healthcare and technology declare that prioritizing health equity necessitates that 
we create systems of accountability; educate ourselves on the causes and implica-
tions of health inequity; and set our aim ultimately at structural interventions.
9.3 Promoting and establishing additional safeguards
As previously discussed, patients, advocates, and other health professionals are 
deeply concerned that current legal parameters and regulatory schemes are not 
robust enough to protect them from the ill effects of potential misuse including 
health data breaches and medical data-mining. In addition to patients, legal schol-
ars, biomedical researchers, computer scientists, and genetic privacy experts are 
sounding the call for a legal overhaul of the statutes affording protections based on 
medical data-sharing and for genetic information, in particular.
Taking the example of genomics and genetics research in a U.S. context, legal 
experts reason that as genetic information is no longer adequately safeguarded 
by the protections of HIPAA and GINA, Congress and other legislative bodies 
may need to pass a broadly applicable, special-purpose genetic privacy law. These 
researchers also deem it necessary for US policymakers to address the issue of 
de-identified genetic data. Although legislatures could regulate DNA as personal 
identifying information in attempt to redress the legal loopholes of genetic gene-
alogy, LawSeq affiliates caution that such a law would not prevent individuals 
from adding their personal genomes to online databases for ancestry purposes. 
As a result, Joh and other legal scholars assert that state legislatures and attorneys 
general can and must act to set up guidelines concerning genetic surveillance and 
policing by law enforcement agencies while, in addition, Congress and the Federal 
Trade Commission could address the privacy and security issues of consumer 
genetic data [27]. Although legal experts do not necessarily advocate for stricter 
controls on genetic data within biomedical contexts, they do stress the need to 
regulate the practices of commercial genetic testing companies and data mining 
firms. Fortunately, many consumer testing companies are invested in preserving 
the trust of their customers. A few have formed an inter-market privacy coalition, 
re-committed to strengthening their consent clauses, and released public state-
ments declaring they are opposed to willingly cooperating with law enforcement 
[28]. Given that it is virtually impossible to ensure anonymity for genetic informa-
tion, researchers in medicine, law, and computer science also recommend establish-
ing restrictions on how genetic data are stored and repurposed. Some, like Yaniv 
Erlich, endorse the idea of attaching cryptographic signatures to genetic profiles 
and using blockchain technology to curb potential abuses. Others advocate for 
utilizing methods of obfuscation. One of these methods of obfuscation is referred 
to as “differential privacy” [29]. In this method, noise is introduced to portions of 
the genetic profile to prevent re-identification and repurposing of the data as well as 
to control access [29]. Nevertheless, the majority of experts across the fields of law, 
biomedical science, healthcare, and computer science are unanimous in asserting 
the urgency for stronger legislative protections.
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In addition to supporting more comprehensive regulatory and legal schemes for 
protecting patients’ data, patients also want to know how algorithmic systems for 
medical usage will be audited for safety. They are further concerned with how regu-
latory agencies will account for the fact and monitor AI systems for use in oncology 
context given these systems require regular updates. Will each update be monitored 
for safe use? How will these bodies guarantee standardization measures for these 
updates? Who will be responsible for potential instances of malfunction or medical 
error pertaining to these systems? Patients stressed that legislators, technologists, 
legal experts, and bioethicists must all be involved in producing answers to these 
queries and in establishing the necessary auditing agencies to assure enforcement 
and cooperation.
Still, patients offered yet another crucial safeguard that can be implemented 
across most university-related research institutes and research-driven corporate 
enterprises with relative ease: the involvement of patient advocates in overseeing 
studies. One patient advocate explained: “If I can throw in my two cents, I would 
encourage companies to involve patients and advocates sooner rather than later. 
And to set up a patient advisory board sooner rather than later even if they are still 
in development. Because they are going to give straight up advice and they are going 
to have knowledge and perspectives that researchers haven’t thought of. There’s no 
question they will. Researchers don’t know what they don’t know when it comes 
to working with patients. But if you bring them in sooner rather than later, they 
can learn as they go along.” As this patient advocate contends, patients, especially 
trained advocates, can offer incisive critiques and help guide researchers in reducing 
the potential for harm, irritating pragmatic issues, and major complications patients 
might encounter as a result of a study or product. Patient advocates can provide 
invaluable guidance and intellectual, sociological, and psychological insight into 
what issues are most pertinent and compelling to patients and how best researchers 
and research institutions can address their needs and concerns.
10. Conclusion
Researchers assert that AI systems can be understood as constitutive of collective 
contestations of the political realities, ethical liabilities, and financial viabilities 
immanent to their social production. Following this logic, studying the patient 
perceptions of AI and AI-led oncology drug development, listening to patient 
perspectives, and heeding their concerns constitutes a cooperative entry point to 
preventing harm, avoiding unnecessary risks, and building networks of public 
consent and approval.
This chapter examined: patient perceptions of AI-enabled healthcare and pres-
ent inclination to trust these tools to improve health outcomes; the extent to which 
they express a desire to be involved in the development of proposed AI systems 
vis-a-vis data-sharing based on their existing knowledge; the concerns and ques-
tions they bear regarding the integration and deployment of these technologies; the 
recommendations and suggestions they are proposing for ensuring patient trust; 
and finally, what patient-centered approaches to building frameworks of trust 
and accountability other researchers of medicine and algorithmic deployment are 
advancing. While this study found cancer patients hold an openness to participating 
in research and a general optimism for experimental endeavors related to improving 
patient outcomes that includes AI-led systems research and use, it also discovered 
that patients maintain a vast array of concerns that must be addressed to protect 
patients from a series of potential risks and existing avenues for medical harm and 
neglect. Specifically, this study discerned that cancer patients are troubled by: a 
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lack of clarity and protections surrounding medical data usage, the potential for 
emerging technologies to exacerbate existing healthcare inequities, and anemic 
approaches to resource-sharing, consent procedures, and educational initiatives to 
bolster research participation and patient trust.
Still, this qualitative study maintains limitations in its scope and aims, its dis-
coveries and discussion. Further research, including quantitative research, may of 
course aid in parsing out the complexities of understanding cancer patients’ varied 
responses to relevant oncology-specific, technological developments. In particular, 
this study could be bolstered by additional comparative, cross-cultural research 
regarding the distinctions between U.S. and U.K. patients and how their contrast-
ing medical care systems may affect their healthcare experiences and impact their 
positions toward burgeoning medical technologies.
Patient approval and participation are not only imperative to developing and 
improving AI-systems given the need for vast amounts of patients’ medical data 
but also to ensuring the use and future widespread adoption of these tools which 
possess the potential to improve patient outcomes. It is crucial to attend to patients’ 
concerns, establish stronger frameworks for ensuring patient trust, and implement 
accountability infrastructures.
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